Compositions and methods for treating SARS-COV-2 infection
By using a combination of bismuth(III)-containing compounds and small molecule thiols to inhibit the SARS-CoV-2 helicase protein, the problem of insufficient efficacy of existing drugs in severe COVID-19 patients was solved, resulting in a significant reduction in symptoms and inhibition of viral replication.
Patent Information
- Application Number
- CN202180039588.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-06-01
- Filing Date
- 2021-05-31
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-05-31
AI Technical Summary
Existing drugs for treating COVID-19, such as remdesivir, have not shown significant clinical benefit in severely ill patients, and there is a lack of effective compositions and methods for treating COVID-19.
Combinations of bismuth (III) compounds with small molecule thiol-containing compounds, such as colloidal bismuth subcitrate, ranitidine bismuth citrate, Bi(TPP), and Bi(TPyP), are used to inhibit SARS-CoV-2 helicase proteins and reduce associated symptoms.
It effectively reduces COVID-19-related symptoms such as fever, sinus and lung congestion, cough, and sore throat, and inhibits viral replication, showing significant therapeutic effects.
Smart Images

Figure BDA0003973459540000021 
Figure BDA0003973459540000022 
Figure BDA0003973459540000023
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of the filing date of U.S. Provisional Application No. 63 / 032,888, filed on June 1, 2020, the entire contents of which are incorporated herein by reference. Field of the Invention
[0003] The present invention is generally in the field of compositions and methods for treating SARS-CoV-2 infection. Background of the Invention
[0005] Currently, there is a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 The coronavirus disease 2019 (COVID-19) pandemic represents a global public health crisis, resulting in approximately 5 million confirmed cases worldwide, including 323,000 deaths. The emergency presents an unprecedented challenge to rapidly identify effective preventive and therapeutic agents. 2 Similarly, SARS-CoV-2 synthesizes a series of viral enzymes and proteins that are essential for viral entry, replication, and pathogenesis, including structural proteins and nonstructural proteins (nsp). Intervention of viral entry or replication may allow the development of vaccines or therapeutics. 3-6 Some enzymes including RNA-dependent RNA polymerase, 3-chymotrypsin-like protease, and papain-like protease 7-9 It may serve as a promising target for potential therapeutic drugs.
[0006] Given the urgency and severity of the pandemic, repurposing drugs already in clinical use to treat COVID-19 is the only practical approach 10,11 It has been reported that remdesivir, a broad-spectrum antiviral drug, has a 12 Remdesivir showed real but not significant benefits, with the median time to recovery reduced by about 4 days from 15 days, and the mortality rate also decreased. 13 However, no significant clinical benefit of remdesivir treatment was observed in patients with severe COVID-19. 14 Overall, current clinical trials of a range of antiviral drugs demonstrate the enormous challenges of improving clinical outcomes for patients with COVID-19. 10,15 Therefore, renewed efforts are most urgently needed. Compositions that are effective in treating COVID-19 are still needed.
[0007] It is an object of the present invention to provide compositions for treating symptoms associated with SARS-CoV-2 infection.
[0008] Another object of the present invention is to provide methods for treating one or more symptoms associated with SARS-CoV-2 infection. SUMMARY OF THE INVENTION
[0010] Disclosed are compositions and methods for treating SARS-CoV-2 infection in a subject in need thereof. The composition comprises one or more bismuth (III) containing compounds, analogs thereof, or pharmaceutically acceptable salts thereof, in a pharmaceutically acceptable carrier, alone or in combination with a thiol-containing small molecule. A preferred thiol-containing small molecule is NAC. In a preferred embodiment, the composition comprises one or more compounds selected from the group consisting of:
[0011]
[0012] Colloidal bismuth subcitrate;
[0013]
[0014] Ranitidine bismuth citrate (RBC);
[0015]
[0016] Bi(TPP) (TPP: tetraphenylporphyrin salt); and
[0017]
[0018] Bi(TPyP) (TPyP: tetrakis(4-pyridyl)porphyrin).
[0019] A bismuth (III)-containing compound or a pharmaceutically acceptable salt thereof is administered alone or preferably in combination with a thiol-containing small molecule to reduce one or more symptoms of a disease, disorder or condition associated with SARS-CoV-2 infection. A preferred thiol-containing small molecule is NAC.
[0020] Also disclosed are methods for treating SARS-CoV-2 infection in a subject in need thereof. The method comprises administering to the subject a composition comprising one or more bismuth (III) compounds, analogs thereof, or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier, alone or in combination with a thiol-containing small molecule, in a therapeutically effective amount to reduce one or more symptoms of SARS-CoV-2 infection. In a preferred embodiment, the treatment effectively inhibits the helicase protein of SARS-CoV-2 in the subject, i.e., the composition is administered in an effective amount to inhibit the helicase protein of SARS-CoV-2 in the subject.
[0021] The treatment is effective in reducing one or more symptoms associated with COVID-19, including, but not limited to, fever, sinus and / or lung congestion, runny or stuffy nose, cough, sneezing, sore throat, body aches, fatigue, shortness of breath, chest tightness, wheezing when exhaling, chills, muscle aches, headache, diarrhea, tiredness, nausea, vomiting, and combinations thereof.
[0022] The composition can be administered to a subject currently suffering from SARS-CoV-2 infection, optionally, the subject is showing one or more symptoms of COVID-19. The composition can also be administered to a subject who has been exposed to SARS-CoV-2 but is asymptomatic. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figures 1A-1H Results are shown for VeroE6 and Caco2 cells infected with SARS-CoV-2 (0.1 MOI) and treated with different concentrations of Pylorid and related compounds as indicated. Intracellular viral loads were measured 48 hours after infection and normalized to human β-actin ( Figures 1A-1D Vero E6 cells, Figure 1E-1H for Caco2 cells). Figure 1M-1P : Virus copy number in cell culture supernatant was determined by qRT-qPCR at 48 h post-infection ( Figures 1I-1L Vero E6 cells, Figure 1M-1P for Caco2 cells).
[0025] Figure 2A : Quantification of antigen-positive cells from randomly selected 800×800 pixel areas (n=4) during two independent experiments (one-way analysis of variance, ANOVA, time-of-drug-addition assay to determine the step of the viral replication cycle targeted by each of the four drug compounds). Figure 2B is a scheme showing the experimental design indicating the period of cell-compound incubation. Virus adsorption was performed at approximately 0-1 h (MOI=2) followed by replacement of fresh medium supplemented with test drug or DMSO. Figure 2C A bar graph is shown showing the virus yield in the supernatant of all groups, quantified by qRT-PCR at 9 hours post infection. One-way ANOVA was used to compare the treated groups with the negative control group (0 μM, 0.1% DMSO). NP represents the nucleocapsid protein of SARS-CoV-2. Figure 2DHEK293-hACE2 stable cells were infected with fake SARS-CoV-2-Luc in the presence of DMSO or drug compounds as shown (n=3). Luciferase activity was measured 48 hours after infection and normalized to the percentage of DMSO control. One-way ANOVA was used to compare the treatment group with the negative control group (0 μM, i.e. 0.1% DMSO). The results are shown as mean ± standard deviation (SD). *p means <0.05, **p means <0.01 and ***p means <0.001. All experiments were performed in triplicate and repeated twice. Figure 2E : Virus copy number in cell culture supernatant after treatment of SARS-CoV-2 infected VeroE6 cells (0.1 MOI, 48 hours after infection) with ranitidine. One-way ANOVA was used to compare the treated group with the negative control group (0 μM, i.e. 0.1% DMSO). Results are shown as mean ± standard deviation (SD). ns indicates not significant. Figure 2F : Vero E6 and Calu-3 cells were infected with pseudo SARS-CoV-2-Luc in the presence of vehicle (water) or RBC (500 μM). Vero E6 and Calu-3 cells were infected with pseudo SARS-CoV-2-Luc in the presence of vehicle (water) or RBC (500 μM). Luciferase activity was measured 48 h after infection and normalized to the percentage of infected cells without any treatment. Results are shown as mean ± SD of n = 3 biologically independent samples. Statistical significance was calculated using an unpaired two-tailed Student's t-test, and **p < 0.01 was tested using the Student's t-test. The gray dotted line represents the mean of the RBC-treated Vero E6 group, which is to make it easier to compare with the mean of the RBC-treated Calu-3 group.
[0026] Figure 3A-3B A study on hamsters (n=5) was shown, in which hamsters were inoculated intranasally with 1000 PFU of SARS-CoV-2 and given Pylorid or Remdesivir or PBS intraperitoneally for 4 consecutive days, with the first dose given 6 hours after infection. Four days after infection, the qRT-PCR assay ( Figure 3A ) and TCID 50 test( Figure 3B ) Respiratory tissue virus production in nasal turbinates and lung tissues of hamsters was detected. Figure 3C : Representative chemokines and cytokines of lung tissues of the indicated groups as detected in lung tissue homogenates 4 days after infection. Results are shown as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the DMSO group. One-way ANOVA. Figure 3D-3E Shown is the purification of SARS-CoV-2 helicase. Figure 3D: SDS-PAGE gel of SARS-CoV-2 helicase. Left lane: marker; right lane: helicase. Figure 3E : Size exclusion chromatogram of SARS-CoV-2 helicase. Figure 3F : Histological score indicating the severity of lung histopathology in each group. The scoring method is detailed in the Methods section. Data are shown as the mean ± SD of four randomly selected sections from each group. Unpaired two-tailed Student's t-test, ***P < 0.001 when compared with the DMSO control group. The histological score of mock infection was set to zero.
[0027] Figures 4A-4D Shown is the inhibition of the ATPase activity of the SARS-CoV-2 helicase by different concentrations of Pylorid and related compounds as indicated. Figure 4E-4H : Titration of the DNA unwinding activity of SARS-CoV-2 helicase by a FRET-based assay with different concentrations of Pylorid and related compounds as indicated. Figures 4A-4H : Data are expressed as a percentage of the control response in the absence of inhibitor. Half maximal inhibitory concentration (IC 50 ) values were determined by nonlinear regression. Figures 4I-4H : After supplementation with different ratios of zinc(II) as shown, the (i) ATPase and ( Figure 4J )Restoration of DNA unwinding activity. Figures 4A-4J : All experiments were performed in triplicate and the data are shown as mean ± SD. Figure 4K-4L :Lineweaver-Burk plot showing the effect of Pylorid on SARS-CoV-2 helicase ( Figure 4K )ATPase activity and ( Figure 4L ) Kinetic inhibition of DNA unwinding activity. In the presence of different concentrations of Pylorid, the effect of the inhibitor on the enzyme is a function of 1 / rate (1 / V 0 ) is determined from a double reciprocal plot of 1 / substrate concentration. i Values were calculated by the intersection of the curves obtained by plotting 1 / V versus inhibitor concentration.
[0028] Figure 5A Different UV-Vis spectra showing different molar equivalents of Bismuth(III) titrated relative to apo-SARS-CoV-2 helicase. The inset shows the titration curve plotted against the molar ratio of [Bismuth(III)] / [apo-SARS-CoV-2 helicase] at about 340 nm. The experiment was performed twice and representative data are shown. Figure 5B: Displacement of zinc(II) in SARS-CoV-2 helicase by pylorid during equilibrium dialysis. Metal contents of zinc(II) and bismuth(III) were determined by ICP-MS. Means of three replicates are shown, error bars represent ±SD.
[0029] Figures 6A-6I : NAC stabilizes and promotes the absorption of the bismuth drug CBS in vitro and in vivo. Fig. 6A Shown is the in vitro chemical stability of CBS (2.5 mM) at pH 1.2 (left), pH 7.4 (middle) and pH 9.2 (right) in the presence of increasing amounts of NAC. The percentage of remaining bismuth was calculated from the ratio of the bismuth content in the supernatant measured at 1 hour to 0 hours (n=3). Figure 6B : Bismuth accumulation of three bismuth drugs in the acidic iso-pH 1.2 receptor compartment in the absence and presence of appropriate amounts of NAC using a PAMPA permeation assay (n=3). Figure 6C : Time-dependent accumulation of bismuth in the receptor compartment of CBS (150 μM) in the absence and presence of 10 NAC (1.5 mM) in a Caco-2 cell monolayer model (n=3). Fig.6D : Bismuth accumulation in Caco-2 cell monolayers (n=3). Fig. 6E : Apparent permeability coefficients (P) of CBS (150 μM) and CBS (150 μM) + 10 NAC (1.5 mM) through Caco-2 monolayers app , cm / s)(n=3). Fig. 6F : Cumulative amount of bismuth transported through the duodenum by CBS (200 μM) versus time in the presence of increasing amounts of NAC in the everted rat intestinal pouch model (n=3). Figure 6G : Blood bismuth concentrations 1 and 2 hours after oral administration of CBS (150 mg / kg) to Balb / c mice in the presence of increasing amounts of NAC (n=3). Figure 6H : Mean blood bismuth concentration versus time curve of CBS and CBS (150 mg / kg) + 10 NAC (610 mg / kg) after oral administration in SD rats (n=5 for each time interval). Fig.6I : Distribution of bismuth in different organs after oral administration of CBS and CBS+10NAC in SD rats (n=5). Samples were collected from Figure 6H The samples were collected from the same batch of rats. Fig. 6A -I: The measurement of drug concentration was based on the metal content obtained by using ICP-MS. Data are shown as mean ± SD. Statistical significance was calculated using unpaired two-tailed Student's t-test, ***P < 0.001, **P < 0.01, *P < 0.05.
[0030] Figures 7A-7D The effect of CBS+3NAC on the replication of human pathogenic coronavirus in a human cell model is shown in a dose-dependent manner (n=3). Fig. 7A : SARS-CoV-2 in Vero E6 cells. Figure 7B : SARS-CoV-2 (B.1.1.7 variant) in Vero E6 cells. Figure 7C : MERS-CoV in Vero E6 cells. Fig.7D : HCoV-229E in HELF cells. Viral load in cell culture supernatant was quantified by qPCR (RT-qPCR) using reverse transcription. Data are shown as mean ± SD. All statistical analyses were compared with the control group (0 μM), and significance was calculated using unpaired two-tailed Student's t-test, ***P<0.001, **P<0.01, *P<0.05. Fig. 7E : Quantification of NP-positive cells from randomly selected 800×800 pixel areas (n=4) during two independent experiments (one-way analysis of variance, ANOVA). ****p<0.0001, **p<0.01. Data are shown as mean±SD. Figure 7F : In the time course of drug addition experiments, the virus yield in the supernatant of all groups was quantified by qRT-PCR at 9 hours after infection (n=3). Data are shown as mean ± SD. One-way ANOVA was used to compare the treatment groups with the vehicle control group (0 μM). ****p<0.0001, **p<0.01, *p<0.05. Figure 7G : Describes a regimen of therapeutic treatment via oral administration of vehicle, CBS (300 mg / kg), NAC (370 mg / kg), and CBS (300 mg / kg) + 3NAC (370 mg / kg) on days -2, -1, 0, and 1, and hamsters were challenged with virus on day 0; tissue samples were collected two days after infection. Figure 7H : Virus yield in hamster lung tissue (n=8). Fig.7I : Expression level of cytokine IL-6 gene. Figures 7H-7I : Data are shown as mean ± SD. Statistical significance was calculated using Kruskal-Wallis with Dunn's multiple comparison test. ***P < 0.001. Figure 7J : Quantification of NP-positive cells from randomly selected 800×800 pixel areas (n=4) in lung tissue (one-way analysis of variance, ANOVA). ****p<0.0001, *p<0.05. Data are shown as mean±SD. Figure 7K:Semiquantitative histological scores were given to each lung tissue by grading the severity of injury in bronchioles, alveoli and blood vessels and accumulating the total score. The histological score of mock infection was set to zero. Data are shown as mean ± SD. Statistical significance was calculated using unpaired two-tailed Student's t-test, ****P<0.0001, **P<0.01, *P<0.05. Figure 7L : Virus copy number in culture supernatant of Vero E6 cells after NAC treatment (n=3). Data are shown as mean±SD. No statistically significant differences were found between the groups using unpaired two-tailed Student's t-test. Figure 7M : Bismuth accumulation in the lungs after oral administration of CBS (150 mg / kg) + 10 NAC (610 mg / kg) for 1 day, 2 consecutive days, and 3 consecutive days in Balb / c mice (n=3). Data are shown as mean ± SD. No statistically significant differences were found between the groups using an unpaired two-tailed Student's t-test.
[0031] Figures 8A-8L : Bismuth drugs exhibit antiviral efficacy by targeting multiple conserved key cysteine proteases / enzymes in SARS-CoV-2. Fig. 8A -D: CBS+3NAC pair ( Fig. 8A ) dsDNA unwinding activity of SARS-CoV-2Hel, ( Figure 8B ) ATPase activity of SARS-CoV-2Hel, ( Figure 8C )SARS-CoV-2PL pro active,( Fig.8D )SARS-CoV-2M pro Inhibition of activity (n=3). Fig. 8E -F: Display CBS+3NAC pairs ( Fig. 8E )SARS-CoV-2PL pro active,( Fig.8F )SARS-CoV-2M pro Lineweaver-Burk plot of the kinetics of activity inhibition. The effect of CBS+3NAC on the enzyme in the presence of different concentrations of CBS+3NAC was determined from a double reciprocal plot of 1 / rate (1 / V) versus 1 / substrate concentration. K i Values were calculated by the intersection of the curves obtained by plotting 1 / V for each substrate concentration versus inhibitor concentration. Figure 8G-8H :Bi 3+ (20 molar equivalents) and ( Figure 8G )SARS-CoV-2PL pro and( Figure 8H )SARS-CoV-2M proThe absorbance dependence of the reaction at 340 nm on time. The curves are shown as nonlinear least squares fits using a one-phase exponential function. Figures 8I-8J :Different molar equivalents of Bi 3+ Titration ( Figure 8I )apo-SARS-CoV-2PL pro and( Figure 8J )SARS-CoV-2M pro The inset shows the difference in UV-visible spectra at about 340 nm for ( Figure 8I )[Bi 3+ ] / [apo-SARS-CoV-2PL pro ]and( Figure 8J )[Bi 3+ ] / [SARS-CoV-2M pro The experiment was performed twice and representative data are shown. Figure 8K : With gradually increasing concentrations of Bi 3+ After incubation, SARS-CoV-2 PL pro Released Zn 2+ (n=3). Figure 8L : with Bi 3+ SARS-CoV-2M after incubation pro Semiquantification of free cysteine in Ellman's test (n=3). Figures 8A-8D , 8K, 8L: Data are shown as mean ± SD.
[0032] Figures 9A-9C : Oral administration of CBS+3NAC showed reversible pathological changes in the kidneys of mice, such as ( Fig. 9A ) Weight change relative to time, ( Fig. 9B ) BUN level relative to time (n = 4), ( Fig. 9C ) revealed by creatinine levels over time (n=4). Data are shown as mean±SD. No statistically significant differences were found between the groups using an unpaired two-tailed Student's t-test.
[0033] Fig. 10A CBS showed that it is effective against SARS-CoV-2PL pro Inhibition of activity. Fig. 10B Show CBS against SARS-CoV-2M pro Inhibition of activity (n=3). Data are shown as mean±SD.
[0034] Fig.11Shown are the effects of co-administration of bismuth and thiol-containing drugs on SARS-CoV-2 in Vero E6 cells. Data are shown as mean ± SD. All statistical analyses were compared with the control group (0 μM), and significance was calculated using an unpaired two-tailed Student's t-test, **P < 0.01. DETAILED DESCRIPTION OF THE INVENTION
[0036] I. Definitions
[0037] As used herein, "carrier" or "excipient" refers to an organic or inorganic ingredient, natural or synthetic inactive ingredient, in a formulation with which one or more active ingredients are combined.
[0038] As used herein, "therapeutically effective" or "effective amount" means that the amount of the composition used is an amount sufficient to improve one or more causes or symptoms of a disease or disorder. Such improvement only requires reduction or modification, not necessarily elimination. As used herein, the terms "therapeutically effective amount", "therapeutic amount" and "pharmaceutically effective amount" are synonymous. One skilled in the art can readily determine an appropriate therapeutic amount.
[0039] "Individual," "host," "subject," and "patient" are used interchangeably herein and refer to animals, particularly mammals, including but not limited to primates, such as humans.
[0040] As used herein, "pharmaceutically acceptable" refers to non-toxic materials that do not interfere with the effectiveness of the biological activity of the active ingredients.
[0041] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the compounds defined herein wherein the parent compound is modified by making acid or base salts thereof.
[0042] As used herein, "treatment" refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
[0043] II. Composition
[0044] Disclosed are bismuth (III) containing compounds whose pharmaceutical formulations can be used alone or preferably in combination with one or more thiol-containing small molecules to treat subjects infected with SARS-CoV-2.
[0045] A. Compounds
[0046] The disclosed compounds include bismuth (III)-containing compounds and thiol-containing small molecules.
[0047] (i) Bismuth (III) containing compounds
[0048] Preferred bismuth-containing compounds for use in the disclosed methods include bismuth (III) citrate-based drugs (complexes of bismuth (III) and citric acid) or bismuth (III) porphyrins. Specific examples include, but are not limited to, bismuth subcitrate, particularly colloidal bismuth subcitrate (CBS).
[0049]
[0050] CBS is a complex bismuth salt of citric acid, which is soluble in water but precipitates at a pH below 5. In gastric fluid, the optimum pH for precipitation is 3.5. CBS can be formulated into a pharmaceutical composition in solid dosage forms for oral administration, such as tablets and capsules.
[0051] or
[0052] Ranitidine bismuth citrate (RBC):
[0053]
[0054] Bi(TPP) (TPP: tetraphenylporphyrin)
[0055]
[0056] Bi(TPyP): (TPyP: tetrakis(4-pyridyl)porphyrin)
[0057]
[0058] (ii) Thiol-containing small molecules
[0059] The molecular weight of the thiol-containing small molecule is preferably less than 2000 Daltons, more preferably less than 1500 Daltons, and most preferably less than 1000 Daltons.
[0060] A preferred thiol-containing small molecule is N-acetylcysteine (NAC). NAC is an FDA-approved drug commonly used as a mucolytic in patients with pneumonia and various other medical conditions, such as paracetamol overdose. (12) NAC is available as an intravenous (IV) medication, an oral medication, and an inhaled medication. (13,14) It is generally safe, has few clinical side effects, and also exhibits antioxidant, anti-inflammatory, and immunomodulatory effects (15,16) However, other thiol-containing compounds are known that contain a sulfur moiety, a thiol moiety, an aminothiol moiety, or a thioester moiety. Examples include glutathione (GSH), penicillamine (PCM), captopril (CPL), and thiosalicylic acid (TSA), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, dimecarprol, D-β,β-dimethylcysteine, and thiolamifotin (Ethyol or WR2721).
[0061] B. Preparation
[0062] The disclosed bismuth (III) compounds or pharmaceutically acceptable salts thereof can be formulated in a pharmaceutical formulation. The thiol-containing small molecule can be formulated in the same pharmaceutical formulation as the bismuth (III) compound or pharmaceutically acceptable salt thereof, and in this embodiment, an effective amount of the thiol-containing small molecule to stabilize the bismuth (III) compound or pharmaceutically acceptable salt thereof at low pH, such as pH 1.2, will be included. The thiol-containing small molecule can be formulated in a separate pharmaceutical formulation.
[0063] The pharmaceutical preparations can be used for parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection) administration, enteral administration.
[0064] The formulation is prepared using a pharmaceutically acceptable "carrier" which consists of a substance that is considered safe and effective and can be administered to an individual without causing undesirable biological side effects or unwanted interactions. A "carrier" is all components present in a pharmaceutical formulation other than the active ingredient or ingredients. The term "carrier" includes, but is not limited to, diluents, binders, lubricants, disintegrants, fillers, and coating compositions.
[0065] In a preferred embodiment, the preparation is in the form of a tablet or capsule or colloidal suspension. In another preferred embodiment, the compound is in a form suitable for intramuscular or intravenous injection. WO1999011848 discloses a swallowable (tablet) form of CBS. Ranitidine bismuth citrate can be conveniently formulated into tablets (including chewable tablets), capsules (hard or soft types) or into liquid preparations, such as described in British Patent Nos. 2220937A and 2248185A. Generally, tablets are preferred. Therefore, the composition can be prepared by conventional methods with additional carriers or excipients, such as binders (e.g., pregelatinized corn starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silicon dioxide); disintegrants (e.g., starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). Basic salts of the type described in British Patent Specification No. 2248185A may be added to improve the disintegration rate and / or dissolution rate of the composition. The tablets may be coated by methods well known in the art. The formulation may also contain flavorings, coloring agents and / or sweeteners as appropriate.
[0066] Tablets can be prepared, for example, by direct compression of such a mixture. Capsules can be prepared by filling the blend together with suitable excipients into gelatin capsules using a suitable filling machine.
[0067] 1. Parenteral preparations
[0068] The compounds described herein may be formulated for parenteral administration.
[0069] For example, parenteral administration can include intravenous administration, intradermal administration, intraarterial administration, intraperitoneal administration, intralesional administration, intracranial administration, intraarticular administration, intraprostatic administration, intrapleural administration, intratracheal administration, intravitreal administration, intramuscular administration, subcutaneous administration, subconjunctival administration, intracapsular administration, intrapericardial administration, intraumbilical administration, injection administration and infusion administration to a patient.
[0070] Parenteral formulations can be prepared as aqueous compositions using techniques known in the art. Generally, such compositions can be prepared as injectable formulations, for example, solutions or suspensions; solid forms suitable for preparing solutions or suspensions after adding a reconstitution medium prior to injection; emulsions, such as water-in-oil (w / o) emulsions, oil-in-water (o / w) emulsions and microemulsions thereof, liposomes or emulsomes.
[0071] The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, one or more polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), oils such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.), and combinations thereof. For example, appropriate fluidity can be maintained by maintaining the desired particle size and / or by using a surfactant, using a coating such as lecithin in the case of dispersion. In many cases, it will be preferred to include an isotonic agent, such as a sugar or sodium chloride.
[0072] Solutions and dispersions of the active compound as a free acid or base or a pharmaceutically acceptable salt thereof can be prepared in water or another solvent or dispersion medium suitably mixed with one or more pharmaceutically acceptable excipients, including but not limited to surfactants, dispersants, emulsifiers, pH adjusters, viscosity adjusters, and combinations thereof.
[0073] Suitable surfactants can be anionic, cationic, amphoteric or nonionic surfactants. Suitable anionic surfactants include, but are not limited to, surfactants containing carboxylate, sulfonate and sulfate ions. Examples of anionic surfactants include long-chain alkyl sulfonates of sodium, potassium and ammonium and alkyl aryl sulfonates of sodium, potassium and ammonium, such as sodium dodecylbenzene sulfonate; sodium dialkyl sulfosuccinates, such as sodium dodecylbenzene sulfonate; sodium dialkyl sulfosuccinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; and alkyl sulfates, such as sodium lauryl sulfate. Cationic surfactants include, but are not limited to, quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethyl benzyl ammonium chloride, polyoxyethylene and coconut amine. Examples of the nonionic surfactant include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbate, polyoxyethylene octylphenyl ether, PEG-1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, 401, stearyl monoisopropanolamide and polyoxyethylene hydrogenated tallow amide. Examples of amphoteric surfactants include sodium N-dodecyl-β-alanine, sodium N-lauryl-β-iminodipropionate, myristoylamphoacetate, lauryl betaine and lauryl sulfobetaine.
[0074] The formulation may contain a preservative to prevent microbial growth. Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, sorbic acid, and thimerosal. The formulation may also contain an antioxidant to prevent degradation of the active agent(s).
[0075] The formulation is typically buffered to a pH of 3-8 for parenteral administration following reconstitution. Suitable buffers include, but are not limited to, phosphate buffers, acetate buffers, and citrate buffers.
[0076] Water-soluble polymers are often used in formulations for parenteral administration. Suitable water-soluble polymers include, but are not limited to, polyvinyl pyrrolidone, dextran, carboxymethyl cellulose, and polyethylene glycol.
[0077] Sterile injection can be prepared by mixing the required amount of active compound with one or more of the excipients listed above into a suitable solvent or dispersion medium as required, and then filtering and sterilizing. In general, dispersions are prepared by mixing various sterilized active ingredients into sterile vehicles, and the sterile carrier contains basic dispersion medium and other required components from those listed above. In the case of sterile powders for the preparation of sterile injections, preferred preparation methods are vacuum drying and freeze drying techniques, which produce powders of active ingredients plus any other desired ingredients from their previously sterile filtered solutions. Powders can be prepared in this way, i.e., particles are porous in nature, which can increase the solubility of particles. Methods for preparing porous particles are well known in the art.
[0078] (a) Controlled release preparations
[0079] The parenteral formulations described herein may be formulated for controlled release, including immediate release, delayed release, extended release, pulsatile release, and combinations thereof.
[0080] i. Nanoparticles and microparticles
[0081] For parenteral administration, one or more compounds and optionally one or more additional active agents can be incorporated into microparticles, nanoparticles, or a combination thereof, which provide controlled release of the compound and / or one or more additional active agents. In embodiments where the formulation comprises two or more drugs, the drugs can be formulated into the same controlled release type (e.g., delayed release, extended release, immediate release, or pulsed release), or the drugs can be independently formulated into different release types (e.g., immediate release and delayed release, immediate release and extended release, delayed release and extended release, delayed release and pulsed release, etc.).
[0082] For example, the compound and / or one or more additional active agents can be incorporated into polymer microparticles that provide controlled release of the drug(s). The release of the drug(s) is controlled by diffusion of the drug(s) from the microparticles and / or degradation of the polymer particles by hydrolysis and / or enzymatic degradation. Suitable polymers include ethylcellulose and other natural or synthetic cellulose derivatives.
[0083] Polymers that can be slowly dissolved and form gels in aqueous environments, such as hydroxypropyl methylcellulose or polyethylene oxide, may also be suitable as materials containing drug microparticles. Other polymers include, but are not limited to, polyanhydrides, poly(ester anhydrides), polyhydroxy acids, such as polylactide (PLA), polyglycolic acid (PGA), poly(lactide-co-glycolic acid) (PLGA), poly-3-hydroxybutyrate (PHB) and copolymers thereof, poly-4-hydroxybutyrate (P4HB) and copolymers thereof, polycaprolactone and copolymers thereof, and combinations thereof.
[0084] Alternatively, the drug(s) may be incorporated into micronized particles made of materials that are insoluble in aqueous solution or slowly soluble in aqueous solution but that are degradable in the gastrointestinal tract by means including enzymatic degradation, surfactant action of bile acids and / or mechanical erosion. As used herein, the term "slowly soluble in water" refers to a material that is insoluble in water within a period of 30 minutes. Preferred examples include fats, fatty substances, waxes, waxy substances and mixtures thereof. Suitable fats and fatty substances include fatty alcohols (such as lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol or cetostearyl alcohol), fatty acids and derivatives, including but not limited to fatty acid esters, fatty acid glycerides (mono-, di- and tri-glycerides) and hydrogenated fats. Specific examples include but are not limited to hydrogenated vegetable oils, hydrogenated cottonseed oil, hydrogenated castor oil, which can be obtained under the trade name Hydrogenated oil, stearic acid, cocoa butter and stearyl alcohol obtained. Suitable waxes and waxy materials include natural or synthetic waxes, hydrocarbons and ordinary waxes. Specific examples of waxes include beeswax, sugar wax (glycowax), castor wax, palm wax, paraffin and candelilla wax (candelillawax). As used herein, waxy materials are defined as any material that is generally solid at room temperature and has a melting point of about 30 to 300°C.
[0085] In some cases, it may be desirable to change the speed at which water infiltrates micron particles. For this reason, a rate-controlling (wicking) agent can be formulated with the above-listed fat or wax. The example of rate-controlling material comprises some starch derivatives (e.g., waxy maltodextrin and drum-dried corn starch), cellulose derivatives (e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose and carboxymethyl cellulose), alginic acid, lactose and talcum powder. In addition, a pharmaceutically acceptable surfactant (e.g., lecithin) can be added to promote the degraded of such micron particles.
[0086] Water-insoluble proteins, such as zein, can also be used as materials for forming drug-containing microparticles. In addition, water-soluble proteins, polysaccharides, and combinations thereof can be formulated into microparticles with drugs and then cross-linked to form an insoluble network. For example, cyclodextrin can be complexed with a single drug molecule and then cross-linked.
[0087] ii. Methods for preparing nanoparticles and microparticles
[0088] By known pharmaceutical preparation technology, it is possible to realize encapsulating the drug or incorporating it into the carrier material to manufacture drug-containing micron particles. In the case of preparations in fat, wax or waxy materials, the carrier material is generally heated to more than its melting temperature, and then the drug is added to form a mixture comprising drug particles suspended in the carrier material, the drug dissolved in the carrier material or its mixture. Micron particles can be prepared subsequently by several methods, including but not limited to solidification, extrusion, spray cooling or water-dispersible methods. In a preferred method, wax is heated to more than its melting temperature, the drug is added, and when the mixture is cooled, the molten wax-drug mixture is solidified under constant stirring. Alternatively, the molten wax-drug mixture can be extruded and spheronized to form particles or beads. These methods are known in the art.
[0089] For some carrier materials, it may be desirable to use solvent evaporation techniques to produce drug-containing microparticles. In this case, the drug and carrier material are co-dissolved in a mutual solvent and then the microparticles can be produced by several techniques, including but not limited to forming an emulsion in water or other suitable medium, spray drying or by evaporating the solvent from the bulk solution and grinding the resulting material.
[0090] In some embodiments, the drug in particle form is uniformly dispersed in a water-insoluble or slowly water-soluble material. In order to minimize the size of the drug particles in the composition, the drug powder itself can be ground to produce fine particles before preparation. Jet milling methods known in the pharmaceutical field can be used for this purpose. In some embodiments, the drug in particle form is uniformly dispersed in the wax or waxy substance by heating the wax or waxy substance to above its melting point and adding the drug particles while stirring the mixture. In this case, a pharmaceutically acceptable surfactant can be added to the mixture to promote the dispersion of the drug particles.
[0091] The particles can also be coated with one or more modified release coatings. Solid esters of fatty acids hydrolyzed by lipase can be sprayed onto microparticles or drug particles. Zein is an example of a naturally water-insoluble protein. It can be coated on drug-containing microparticles or drug particles by spraying or by wet granulation technology. In addition to naturally water-insoluble materials, some substrates of digestive enzymes can be treated with a cross-linking process to form an insoluble network. Many methods of cross-linking proteins initiated by both chemical and physical methods have been reported. One of the most common methods to obtain cross-linking is the use of chemical cross-linking agents. Examples of chemical cross-linking agents include aldehydes (glutaraldehyde and formaldehyde), epoxy compounds, carbodiimides, and genipin. In addition to these cross-linking agents, oxidized sugars and natural sugars have also been used to cross-link gelatin. Cross-linking can also be accomplished using enzymatic methods; for example, transglutaminase has been approved as a GRAS substance for cross-linking seafood. Finally, cross-linking can be initiated by physical methods such as heat treatment, ultraviolet irradiation, and gamma irradiation.
[0092] To produce a coating of cross-linked protein around drug-containing microparticles or drug particles, a water-soluble protein can be sprayed onto the microparticles and then cross-linked by one of the methods described above. Alternatively, the drug-containing microparticles can be microencapsulated in protein by coacervation phase separation (e.g., by adding salt) and then cross-linked. Some proteins suitable for this purpose include gelatin, albumin, casein, and gluten.
[0093] Polysaccharides can also be cross-linked to form water-insoluble networks. For many polysaccharides, this can be accomplished by reaction with calcium salts or multivalent cations, which cross-link the main polymer chains. Pectin, alginates, dextran, amylose, and guar gum are cross-linked in the presence of multivalent cations. Complexes between oppositely charged polysaccharides can also be formed; for example, pectin and chitosan can be compounded via electrostatic interactions.
[0094] 2. Intestinal preparations
[0095] Suitable oral dosage forms include tablets, capsules, solutions, suspensions, syrups and lozenges. Tablets can be made using compression or molding techniques well known in the art. Gelatin capsules or non-gelatin capsules can be made into hard or soft capsule shells using techniques well known in the art, which can encapsulate liquid, solid and semi-solid fill materials.
[0096] The formulations can be prepared using a pharmaceutically acceptable carrier. As generally used herein, "carrier" includes, but is not limited to, diluents, preservatives, binders, lubricants, disintegrants, expanders, fillers, stabilizers, and combinations thereof.
[0097] The carrier also includes all ingredients of the coating composition, which may include plasticizers, pigments, colorants, stabilizers and glidants.
[0098] Examples of suitable coating materials are, but are not limited to, cellulosic polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and cellulose polymers available under the trade name Methacrylic resins, zein, shellac and polysaccharides were commercially available from Roth Pharma, Westerstadt, Germany.
[0099] In addition, the coating material may further contain conventional carriers such as plasticizers, pigments, colorants, glidants, stabilizers, pore formers and surfactants.
[0100] "Diluents", also known as "fillers", are often necessary to increase the bulk of a solid dosage form in order to provide a practical size for compression of tablets or formation of beads and granules. Suitable diluents include, but are not limited to, dibasic calcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starch, pregelatinized starch, silicon dioxide, titanium oxide, magnesium aluminum silicate, and powdered sugar.
[0101] "Binders" are used to impart cohesiveness to solid dosage forms and thus ensure that tablets or beads or granules remain intact after forming the dosage form. Suitable binder materials include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (including sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums such as gum arabic, tragacanth, sodium alginate, celluloses including hydroxypropyl methylcellulose, hydroxypropyl cellulose, ethyl cellulose and magnesium aluminum silicate (veegum), and synthetic polymers such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid / polymethacrylic acid and polyvinyl pyrrolidone.
[0102] "Lubricants" are used to facilitate tablet manufacturing. Examples of suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, polyethylene glycol, talc, and mineral oil.
[0103] "Disintegrants" are used to promote disintegration or "breakup" of a dosage form after administration and generally include, but are not limited to, starch, sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethyl cellulose, hydroxypropyl cellulose, pregelatinized starch, clay, cellulose, alginine, gum, or a cross-linked polymer such as cross-linked PVP (from GAF Chemical Corp. XL).
[0104] "Stabilizers" are used to inhibit or delay decomposition reactions of the drug, including, for example, oxidation reactions. Suitable stabilizers include, but are not limited to, antioxidants, butylated hydroxytoluene (BHT); ascorbic acid, its salts and esters; vitamin E, tocopherol and its salts; sulfites, such as sodium metabisulfite; cysteine and its derivatives; citric acid; propyl gallate and butylated hydroxyanisole (BHA).
[0105] (a) Controlled Release Enteral Preparations
[0106] Oral dosage forms, such as capsules, tablets, solutions and suspensions can be formulated for controlled release. For example, one or more compounds and optionally one or more additional active agents can be formulated into nanoparticles, microparticles and combinations thereof, and encapsulated in soft or hard gelatin or non-gelatin capsules, or dispersed in a dispersion medium to form an oral suspension or syrup. The particles can be formed by a drug and a controlled release polymer or matrix. Alternatively, the drug particles can be coated with one or more controlled release coatings before being incorporated into the finished dosage form.
[0107] In another embodiment, one or more compounds and optional one or more other activating agents are dispersed in a matrix material, and the matrix material is gelling or emulsifying when contacting with an aqueous medium such as a physiological fluid. In the case of a gel, the matrix expands, and the activating agent is wrapped, and the activating agent slowly releases over time by the degraded of diffusion and / or matrix material. Such a matrix can be formulated as a tablet or is formulated as a filling material for hard capsules and soft capsules.
[0108] In yet another embodiment, one or more compounds and optionally one or more additional active agents are formulated into a solid oral dosage form, such as a tablet or capsule, and the solid dosage form is coated with one or more controlled release coatings, such as a delayed release coating or an extended release coating. One or more coatings may also contain the compound and / or additional active agent.
[0109] (i) Extended release dosage form
[0110] Extended release formulations are generally prepared as diffusion or osmotic systems, which are known in the art. Diffusion systems generally consist of two types of devices, a reservoir and a matrix, which are well known and described in the art. Matrix devices are generally prepared by compressing the drug with a slowly dissolving polymer carrier into tablet form. The three main types of materials used to prepare matrix devices are insoluble plastics, hydrophilic polymers, and fatty compounds. Plastic matrices include, but are not limited to, methyl acrylate-methyl methacrylate, polyvinyl chloride, and polyethylene. Hydrophilic polymers include, but are not limited to, cellulosic polymers such as methyl cellulose and ethyl cellulose, hydroxyalkyl celluloses such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, and 934, polyethylene oxide and mixtures thereof. Fatty compounds include, but are not limited to, various waxes such as palm wax and glyceryl tristearate and waxy materials including hydrogenated castor oil or hydrogenated vegetable oil or mixtures thereof.
[0111] In certain preferred embodiments, the plastic material is a pharmaceutically acceptable acrylic polymer, including but not limited to copolymers of acrylic acid and methacrylic acid, methyl methacrylate, methyl methacrylate copolymers, ethoxyethyl methacrylate, cyanoethyl methacrylate, aminoalkyl methacrylate copolymers, poly(acrylic acid), poly(methacrylic acid), methacrylate alkylamine copolymers, poly(methyl methacrylate), poly(methacrylic acid) (anhydride), polymethacrylate, polyacrylamide, poly(methacrylic acid anhydride) and glycidyl methacrylate copolymers.
[0112] In certain preferred embodiments, the acrylic polymer is composed of one or more quaternary ammonio methacrylate copolymers. Quaternary ammonio methacrylate copolymers are well known in the art and are described in NF XVII as fully polymerized copolymers of acrylate and methacrylate having a small amount of quaternary ammonium groups.
[0113] In a preferred embodiment, the acrylic polymer is an acrylic resin lacquer, such as available from Rohm Pharma as EUDRAGIT In a further preferred embodiment, the acrylic polymer comprises an acrylic resin paint commercially available under the trade names of RL30D and RS30D is a commercially available mixture of two acrylic resin lacquers. RL30D and RS30D is a copolymer of acrylate and methacrylate with a small amount of quaternary ammonium groups. The molar ratio of ammonium group to other neutral (meth)acrylate in RL30D is 1:20. The molar ratio of ammonium groups to the remaining neutral (meth)acrylates in RS30D is 1:40. The average molecular weight is about 150,000. S-100 and L-100 is also preferred. The code names RL (high permeability) and RS (low permeability) refer to the permeation properties of these agents. The RL / RS mixture is insoluble in water and digestive fluids. However, the formed multiparticulate system comprising the mixture is swellable and permeable in aqueous solutions and digestive fluids.
[0114] The above polymers, such as RL / RS can be mixed in any desired ratio to ultimately obtain a sustained release formulation with a desired dissolution profile. RL, 50% RL and 50% EUDRAGIT RS and 10% RL and 90% RS to obtain the desired sustained release multi-particulate system. Those skilled in the art will recognize that other acrylic polymers may also be used, such as, for example L.
[0115] Alternatively, an osmotic system or a semi-permeable coating can be used to prepare a prolonged release formulation. In the latter case, the desired drug release profile can be achieved by combining a low permeability coating material and a high permeability coating material in an appropriate ratio.
[0116] The above-mentioned devices with different drug release mechanisms can be combined in the final dosage form comprising single or multiple units. The example of multiple units includes but is not limited to multilayer tablets and capsules containing tablets, beads or granules. The immediate release portion can be added to the extended release system by means of the following: the immediate release layer is applied on the top of the extended release core using a coating or compression method, or the immediate release layer is applied to a multi-unit system, such as a capsule containing extended release beads and immediate release beads.
[0117] Extended release tablets containing hydrophilic polymers are prepared by techniques well known in the art, such as direct compression, wet granulation or dry granulation. Their preparations are usually mixed with polymers, diluents, binders and lubricants and active pharmaceutical ingredients. Common diluents include inert powdered substances, such as starch, powdered cellulose, particularly crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, cereal flour and similar edible powders. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or calcium sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders include materials such as starch, gelatin and sugar, such as lactose, fructose and glucose. Natural and synthetic gums including gum arabic, alginates, methylcellulose and polyvinyl pyrrolidone can also be used. Polyethylene glycol, hydrophilic polymers, ethyl cellulose and wax can also be used as binders. In tablet formulations, lubricants are necessary to prevent tablets and punches from sticking in the mold. Lubricants may be chosen from slippery solids such as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.
[0118] The extended release tablet containing wax material is generally prepared by methods known in the art, such as direct blending, solidification and water dispersion. In the solidification method, the drug is mixed with the wax material and spray solidified or solidified and screened and processed.
[0119] (ii) Delayed Release Dosage Form
[0120] Delayed release formulations can be produced by coating a solid dosage form with a polymer film that is insoluble in the acidic environment of the stomach but soluble in the neutral environment of the small intestine.
[0121] For example, delayed release dosage units can be prepared by coating a drug or drug-containing composition with a selected coating material. The drug-containing composition can be, for example, a tablet for incorporation into a capsule, a tablet used as an inner core in a "coated core" dosage form, or a plurality of drug-containing beads, granules or granules for incorporation into a tablet or capsule. Preferred coating materials include bioerodible, gradually hydrolyzable, gradually water-soluble and / or enzymatically degradable polymers, and can also be conventional "enteric" polymers. As will be appreciated by those skilled in the art, enteric polymers become soluble in the higher pH environment of the lower digestive tract, or slowly dissolve as the dosage form passes through the digestive tract, while enzymatically degradable polymers are degraded by bacterial enzymes present in the lower digestive tract, particularly the colon. Coating materials suitable for achieving delayed release include, but are not limited to, cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, and sodium carboxymethyl cellulose; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, and / or ethyl methacrylate, and other methacrylic acid resins, which may be marketed under the trade names (Rohm Pharma; Westerstadt, Germany), including L30D-55 and L100-55 (soluble at pH 5.5 and higher), L-100 (soluble at pH 6.0 and higher), S (soluble at pH 7.0 and higher due to higher degree of esterification), and NE, RL and RS (water-soluble polymers with different degrees of permeability and swellability) are commercially available; vinyl polymers and copolymers such as polyvinyl pyrrolidone, vinyl acetate, vinyl acetate phthalate, vinyl acetate crotonic acid copolymer and ethylene-vinyl acetate copolymer; enzyme-degradable polymers such as azo polymers, pectin, chitosan, amylose and guar gum; zein and shellac. Combinations of different coating materials can also be used. Multilayer coatings using different polymers can also be applied.
[0122] The preferred coating weight for a particular coating material can be readily determined by one skilled in the art by evaluating individual release profiles of tablets, beads and granules prepared with varying amounts of various coating materials. It is the combination of material, method and form of application that produces the desired release profile, which one can only be determined by clinical studies.
[0123] The coating composition can include conventional additives, such as plasticizers, pigments, colorants, stabilizers, slip agents, etc. The presence of plasticizers is usually to reduce the brittleness of the coating, and relative to the dry weight of the polymer, plasticizers will generally account for about 10% by weight to 50% by weight. The example of a typical plasticizer includes polyethylene glycol, propylene glycol, triacetin, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, triethyl citrate, tributyl citrate, acetyl triethyl citrate, castor oil and acetylated monoglyceride. Preferably, stabilizers are used to stabilize the particles in the dispersion. Typical stabilizers are nonionic emulsifiers, such as sorbitan esters, polysorbates and polyvinylpyrrolidone. Slip agents are recommended to reduce the adhesion effect in film formation and drying processes, and slip agents will generally account for about 25% by weight to 100% by weight of the polymer weight in the coating solution. An effective glidant is talc. Other glidants, such as magnesium stearate and glyceryl monostearate, may also be used. Pigments, such as titanium dioxide, may also be used. Small amounts of defoamers, such as silicones (e.g., dimethicone) may also be added to the coating composition.
[0124] As will be appreciated by those skilled in the art and as described in relevant textbooks and literature, several methods can be used to prepare drug-containing tablets, beads, granules or particles that provide various drug release profiles. Such methods include, but are not limited to, the following: coating the drug or drug-containing composition with an appropriate coating material, generally but not necessarily incorporating a polymeric material, increasing the drug particle size, placing the drug in a matrix, and forming a complex with the drug with an appropriate complexing agent.
[0125] The delayed-release dosage unit can be coated with a delayed-release polymer coating using conventional techniques, such as using a conventional coating pan, airless spray technology, fluidized bed coating equipment (with or without a Wurster insert). For detailed information on materials, equipment and methods for preparing tablets and delayed-release dosage forms, see Pharmaceutical Dosage Forms: Tablets, Lieberman et al., ed. (New York: Marcel Dekker, Inc., 1989), and Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 6.sup.th Ed. (Media, PA: Williams & Wilkins, 1995).
[0126] The preferred method for preparing extended release tablets is by compressing a blend containing medicine, for example, a blend of granules prepared using direct blending, wet granulation or dry granulation methods. Extended release tablets can also be molded rather than compressed from the wet material containing a suitable water-soluble lubricant. However, tablets are preferably manufactured using compression rather than molding. The preferred method for forming an extended release blend containing medicine is to directly mix drug particles with one or more excipients, such as diluents (or fillers), adhesives, disintegrants, lubricants, slip agents and colorants. As an alternative to direct blending, a blend containing medicine can be prepared by using wet granulation or dry granulation methods. The pearl containing an active agent can also be prepared by any of several conventional techniques, generally starting from a fluid dispersion. For example, the typical method for preparing a pearl containing a medicine relates to dispersing or dissolving an active agent in a coating suspension or solution containing a pharmaceutical excipient, such as polyvinyl pyrrolidone, methylcellulose, talcum powder, metal stearate, silicon dioxide, plasticizer, etc. The mixture is used to coat bead cores, such as sugar spheres (or so-called "non-pareil"), having a size of about 60 to 20 mesh.
[0127] An alternative method for preparing drug beads is by blending the drug with one or more pharmaceutically acceptable excipients, such as microcrystalline cellulose, lactose, cellulose, polyvinyl pyrrolidone, talc, magnesium stearate, disintegrants, etc., extruding the blend, spheronizing the extrudate, drying and optionally coating to form immediate release beads.
[0128] III. How to use
[0129] Methods for treating SARS-CoV-2 infection in a subject in need thereof are provided. The subject can be a mammal, such as a human. The subject is preferably a human subject. The composition is administered to reduce one or more symptoms associated with SARS-CoV-2 infection. In a preferred embodiment, the composition is administered in an effective amount to inhibit the SARS-CoV-2 helicase.
[0130] In one embodiment, the composition administered is a preparation of one or more bismuth (III) compounds or pharmaceutically acceptable salts thereof as disclosed herein, a preparation of one or more bismuth (III) compounds or pharmaceutically acceptable salts thereof and one or more thiol-containing small molecules, wherein the one or more thiol-containing small molecules are in an effective amount to stabilize the bismuth (III) compound or pharmaceutically acceptable salt thereof at low pH, e.g., pH 1.2.
[0131] In other embodiments, the treatment comprises administering to the subject a formulation of one or more bismuth (III) compounds or pharmaceutically acceptable salts thereof disclosed herein and a formulation of a thiol-containing small molecule, administered simultaneously or sequentially. In this embodiment, the administered thiol-containing small molecule is effective to stabilize the bismuth (III) compound or pharmaceutically acceptable salt thereof at low pH, such as pH 1.2. The thiol-containing small molecule that is effective to stabilize the bismuth (III) compound or pharmaceutically acceptable salt thereof at low pH, such as pH 1.2, is used in an amount of 3 or 10 molar equivalents of the bismuth (III) compound or pharmaceutically acceptable salt thereof.
[0132] A preferred thiol-containing small molecule is NAC.
[0133] In some embodiments, the subject has been or will be exposed to the virus. In preferred embodiments, the subject has been exposed to the virus or is experiencing an active viral infection, which is confirmed by one or more symptoms associated with COVID 19. Symptoms include, but are not limited to, fever, sinus and / or lung congestion, runny or stuffy nose, cough, sneezing, sore throat, body aches, fatigue, shortness of breath, chest tightness, wheezing when exhaling, chills, muscle pain, headache, diarrhea, tiredness, nausea, vomiting, and combinations thereof, and the subject may or may not be diagnosed as having SARS-CoV-2 infection using known methods for testing subjects for infection with SARS-CoV-2. The current gold standard for molecular diagnostics of COVID-19 is based on detection of SARS-CoV-2 RNA by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR).
[0134] The composition may also be administered prophylactically, for example to reduce or prevent the effects of future exposure to the virus and infections that may be associated therewith. Thus, in some embodiments, the subject has not been exposed to the virus and / or has not yet experienced an active viral infection. In some embodiments, the subject is a healthy subject. However, in a particularly preferred embodiment, the composition is administered to improve one or more COVID 19 symptoms in the subject.
[0135] The disclosed methods will be understood by means of the following non-limiting examples.
[0136] In one embodiment, a composition containing a bismuth (III) compound is administered to a subject in an amount effective to reduce one or more symptoms of COVID 19. In a preferred embodiment, the composition contains a bismuth (III) citrate-based drug (a complex of bismuth (III) and citric acid) or a bismuth (III) porphyrin.
[0137] For example, a composition containing an effective amount of a bismuth compound, including but not limited to bismuth subcitrate, such as colloidal bismuth subcitrate (CBS), alone or in combination with a thiol-containing small molecule, such as NAC, can be administered to a subject.
[0138]
[0139] or
[0140] Ranitidine bismuth citrate (RBC:
[0141]
[0142] In other embodiments, a composition comprising a bismuth (III) porphyrin compound, such as Bi(TPP) (TPP: tetraphenylporphyrin salt) may be administered to a subject.
[0143]
[0144] Bi(TPyP): (TPyP: tetrakis(4-pyridyl)porphyrin)
[0145]
[0146] A subject may be treated with one or more of the disclosed compounds, the treatment regimen being effective in reducing one or more COVID 19 symptoms, preferably, the treatment regimen being effective in inhibiting the SARS-CoV-2 helicase.
[0147] Compared to control subjects who were given a bismuth-containing compound without one or more thiol-containing small molecules, the effects of increasing bismuth plasma concentrations, prolonging T 最大 And increase AUC 0→12h The amount of thiol-containing small molecules is given.
[0148] The disclosed methods will be understood by way of the following non-limiting examples. Example
[0149] Materials and methods
[0150] Chemicals, viruses, and cell lines
[0151] Colloidal bismuth citrate (De-Nol / CBS) and ranitidine bismuth citrate (Pylorid) were kindly provided by Livzon Pharmaceutical Group. The RBC used in the current study had a composition of ranitidine: Bi(iii): citric acid = 1:1:1, with a molecular formula of C 19 H 27 N 4 O 10 S 23 Bi(TPP), Bi(TPyP) and Bi(NTA) were prepared as described previously. 36 . Stenosulfuron was purchased from MedChemExpress (MCE). The combination of CBS and NAC was freshly prepared before the experiment by physically mixing CBS and appropriate molar equivalents of NAC and then adjusting the pH to 5-6 with 0.05 M NaOH. Bismuth subsalicylate (BSS) and bismuth subgallate (BGS) were obtained from Alfa Aesar. Bi(NTA) 3 Prepared as described previously (1) Kanamycin sulfate and Luria-Bertani (LB) broth powder were purchased from Affymetrix. All other chemicals were purchased from Sigma-Aldrich unless otherwise stated and used directly without further purification.
[0152] The cell lines used in this study were selected based on their susceptibility to replication of the corresponding coronaviruses.
[0153] SARS-CoV-2 (strain HKU-001a) (GenBank accession number: MT230904) and B.1.1.7 variant (GISAID accession number: EPI_ISL_1273444) were isolated from a nasopharyngeal aspirate sample from a patient with laboratory-confirmed COVID-19 in Hong Kong 37 .
[0154] Human colon epithelial cells (Caco2) and African green monkey kidney (VeroE6) cells and human lung epithelial cells (Calu-3) were purchased from ATCC (without further authentication, confirmed to be free of mycoplasma contamination by PlasmoTest (InvivoGen)) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco, Paisley, UK), 1% penicillin-streptomycin (Gibco BRL, Grand Island, NY, USA) and 1% non-essential amino acids (Gibco BRL, Gibco, Grand Island, NY, USA).
[0155] Monkey Vero E6 cells (ATCC, CRL-1586) were cultured in a medium supplemented with 10% FBS, 50 U mL -1 Penicillin and 50 μg mL -1 The cells were cultured in DMEM containing streptomycin. Human embryonic lung fibroblasts (HELF) were developed in-house. The cells were maintained at 37°C and 5% CO 2 and an atmosphere of 90% relative humidity.
[0156] SARS-CoV-2 pseudovirions (replication-defective murine leukemia virus (MLV) pseudotyped with SARS-CoV-2 spike protein) were purchased from eEnzyme (Cat. No. SCV2-PsV-001). MERS-CoV strain (HCoV-EMC / 2012) was a gift from Dr. Ron Fouchier (3) The hCoV-229E strain was from a previous collection (4,5) As mentioned above 38 All experiments using live viruses were conducted using a biosafety level 3 facility at Queen Mary Hospital, The University of Hong Kong.
[0157] Cell viability assay
[0158] As mentioned above, Luminescence assay (Promega Corporation, Madison, WI, USA) was used to detect the cytotoxicity of selected compounds. 39 Briefly, VeroE6 cells (4 × 10 4 cells) and Caco2 cells (4×10 4Cells) were incubated with different concentrations of single compounds in 96-well plates for 48 h, then substrate was added and brightness was measured after 10 min. Ridaura and Au(PEt3)Cl were dissolved in DMSO and the final percentage of DMSO in the culture medium was kept at 1%. The 50% cytotoxic concentration (CC 50 ) values were calculated by Sigma plot (SPSS) in the Excel plug-in ED50V10.
[0159] animal
[0160] All experiments were approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR) of the University of Hong Kong and were performed in accordance with the guidelines approved by CULATR.
[0161] For mouse experiments, 6- to 8-week-old female BALB / c mice weighing 18-22 g were purchased from Charles River Laboratories, Inc. All animal procedures were approved by the CULATR of the University of Hong Kong (reference code: CULATR 5079-19). For rat-related experiments, Sprague Dawley rats weighing 200-220 g were provided by the Laboratory Animal Services Center of the Chinese University of Hong Kong. Animal experiments were performed with the approval of the Animal Ethics Committee of the Chinese University of Hong Kong (reference code: 19 / 074 / GRF-5-C&(19-589), DH / SHS / 8 / 2 / 1Pt.22). All animals were randomly housed in biosafety-level housing before the start of the corresponding experiment and had free access to standard pelleted diet and water.
[0162] For hamster experiments, 6- to 10-week-old male and female Syrian hamsters weighing 70-100 g were obtained from the Chinese University of Hong Kong Laboratory Animal Service Centre through the HKU Centre for Comparative Medicine Research. Hamsters were housed in biosafety level 2 housing and had free access to standard pelleted diet and water as described previously. (2,7)All experimental protocols were approved by CULATR of the University of Hong Kong and performed in accordance with the standard operating procedures of the Biosafety Level 3 Animal Facility (reference code: CULATR5370-20).
[0163] Analysis of Bismuth by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
[0164] ICP-MS was used to monitor bismuth levels in all subjects studied. A quadrupole-based inductively coupled plasma mass spectrometer (ICPMS) (Agilent 7700x, Agilent Technologies, CA) equipped with a glass concentric nebulizer was used in this study. The samples were diluted to an appropriate concentration, sprayed into an aerosol using a micro-concentric nebulizer, and directly introduced into the ICP for time-resolved ICP-MS measurement. When the measured signal exceeded the linear range of the standard curve, the sample was further diluted. The bismuth content (Bi) in the substance being studied was calculated based on the standard curve in 1% nitric acid or blank control solutions of various organs and blood. 209 ). Only one isotope is monitored in each measurement.
[0165] The main parameters are listed as follows: RF power (1300 kW); spray chamber (Scott spray chamber); nebulizer (MicroMist nebulizer); lens: (Ni); nebulizer gas flow rate (0.8 mL min -1 ); acquisition mode: (TRA time-resolved analysis); residence time: 100 ms; reaction gas (no gas); temperature (2°C). The bismuth standard solution was prepared by diluting a multi-element calibration standard (Fluka Analytical, 90243). An internal standard (10 μg L -1 ; Agilent Technologies, 5188-6525).
[0166] Chemical stability
[0167] Simulated gastric fluid, phosphate-buffered saline, and sodium bicarbonate buffer were used to simulate environments of pH 1.2, 7.4, and 9.2. Simulated gastric fluid was prepared by dissolving NaCl (0.2 g) and pepsin (0.32 g) in about 70 mL of deionized water. The pH was then adjusted to 1.2 with 10 M HCl. The volume was finally adjusted to 100 mL with deionized water. Phosphate-buffered saline was made of 2.7 mM potassium chloride, 1.8 mM potassium dihydrogen phosphate, 137 mM sodium chloride, and 10 mM disodium hydrogen phosphate. The pH was adjusted to 7.4 with HCl. The simulated ...HCO 3 Prepare a 150 mM sodium bicarbonate solution by dissolving in deionized water and adjusting the pH to 9.2.
[0168] To monitor the stability of bismuth-NAC at different pH, bismuth-NAC mixtures of 1:1, 1:3, and 1:10 ratios were prepared by adding appropriate amounts of NAC to 10 mM CBS solution. Each bismuth-NAC (500 μL) was mixed with pH buffer (500 μL) and incubated for 24 hours. The mixture was centrifuged and each supernatant was aliquoted into different tubes as samples, which were subsequently subjected to ICP-MS to measure the remaining bismuth content in the supernatant.
[0169] The bismuth-thiol mixture was prepared by titrating NAC into the bismuth drug solution. The Bi-NAC mixture in a ratio of 1:3 was prepared by adding appropriate amounts of NAC to solutions of CBS (10 mM) and RBC (10 mM), respectively. The mixture of BSG and BSS with NAC was obtained by dissolving appropriate amounts of BSG and BSS powders in NAC (100 mM) at a molar ratio of 1:10, respectively. The Bi-thiol mixture in a ratio of 1:3 was prepared by adding appropriate amounts of reduced glutathione (GSH) and penicillamine (PCM) to CBS (10 mM) solution, respectively. The mixture of CBS and captopril (CPL) was made in a ratio of 1:10. For thiosalicylic acid (TSA), it was first dissolved with 10% DMSO and 30% PEG in deionized water and mixed with the CBS solution in a ratio of 1:1. The bismuth-thiol mixture (2 mL) was then added to the above pH buffer (2 mL). Photos were taken for record and are shown in Figure S1.
[0170] Parallel Artificial Membrane Permeability Assay (PAMPA)
[0171] PAMPA was used to determine the permeation of bismuth in the absence or presence of NAC. Donor (top) solutions were prepared by adding CBS (2.5 mM), CBS (2.5 mM) + 1 NAC (2.5 mM), CBS (2.5 mM) + 3 NAC (7.5 mM), CBS (2.5 mM) + 10 NAC (25 mM), CBS (2.5 mM) + 20 NAC (50 mM) in PBS (pH 1.2). About 5 μL of hen egg lecithin (1% weight / volume) in dodecane was added to the artificial membrane in each well of the donor plate for membrane activation. Subsequently, 400 μL of the receptor solution was added to each well of the receptor plate (BioAssay System, USA) and covered by the donor plate with 200 μL aliquots of the donor solution in each well. The system was incubated at room temperature for 16 hours, and then the bismuth concentration of each substance studied in the starting solution and in the donor solution after incubation was measured by ICP-MS. The experiment was performed in triplicate.
[0172] In vitro Caco-2 permeability assay
[0173] The in vitro permeability of CBS in the absence or presence of NAC was evaluated by using the Caco-2 permeability assay as described previously. (8) .
[0174] Briefly, Caco-2 cells at 80–90% confluence were subcultured by trypsinization with 0.05% trypsin-EDTA (Gibco BRL, Gibco, Grand Island, NY, USA) and plated at 1–2 × 10 5 The cells were plated at a density of 100 cells / mL in six-well Transwell chambers (24 mm inner diameter, 0.4 μm pore size, 4.67 cm) coated with collagen (type I collagen rat tail solution, St. Louis, MO, USA). 2 , polycarbonate filters, Corning Costar Co. NY, USA) and cultured for 21 days before transport experiments. The transepithelial electrical resistance (TEER) value of each well was monitored by an epithelial cell voltmeter (EVOM2, World Precision Instruments Inc., Berlin, Germany) with an STX2 electrode set according to the manufacturer's instructions to ensure the integrity of the monolayer. TEER above 600 Ω cm was used in this study. 2 of cell monolayer.
[0175] For transport studies, CBS (150 μM) and CBS (150 μM) + 10 NAC (1.5 mM) were prepared in transport buffer [Hank's balanced salt solution (pH 7.4, HBSS, Grand Island, NY, USA) containing phenol red] and 1.5 mL aliquots were loaded in the donor (apical) chamber, followed by 2.5 mL of transport buffer in the receptor (basolateral) chamber. 0.1 mL aliquots were withdrawn from the receptor chamber at various time intervals (10, 20, 30, 40, 50, 60 min) and immediately replenished with an equal volume of blank transport buffer in the receptor chamber. Experiments were performed in triplicate. Samples collected from the transport studies were washed with 1% HNO 3 The cells were diluted to the appropriate concentration and then subjected to ICP-MS measurement of the bismuth content transported from the donor side to the acceptor side. At the end of the transport study, the Caco-2 cells on the monolayer were also collected after washing 6 times with PBS and the number of cells was counted using a hemocytometer under a light microscope. The resulting cell pellet was treated with 69% HNO 3 The CBS from different treatment groups was acidified and appropriately diluted for measuring bismuth accumulation in cells. app , cm / s) is calculated by the following formula (9):
[0176]
[0177] Where dQ / dt (μmol / s) is the cumulative concentration at time t, C (μM) is the initial concentration of the test drug in the donor compartment, and A (cm 2 ) is the surface area of a single layer.
[0178] In vitro everted intestinal sac model
[0179] According to the modified method (10,11) An isolated everted intestinal sac model was used. To prepare the everted intestinal sac, the small intestine was quickly isolated from the rat immediately after it was sacrificed and then washed several times with 0.9% saline. The intestinal sac was then washed several times with 0.9% saline in an oxygenated medium [Krebs–Henseleit solution (pH 7.4, 1.25 mM NaHCO 3 , pH 7.4, 5.9mM NaCl, 23.5μM KCl, 60μM MgSO 4 , 62.5 μM CaCl 2 , 60 μM KH 2 PO 4 The duodenum (about 4 cm) was dissected from the intestine in 5% paracentesis (500 μM glucose) and gently everted, cleaned, put on a glass rod, and fixed with braided silk. The duodenum was clamped at one end and filled with 1 mL of fresh oxygenated medium, then sealed with a second clamp to obtain an everted intestinal sac about 3 cm long sutured with braided silk.
[0180] Everted intestinal sacs (n=3 per group) were dialyzed at 37°C in oxygenated medium supplemented with CBS (200 μM), CBS (200 μM) + 1 NAC (200 μM), CBS (200 μM) + 3 NAC (600 μM), CBS (200 μM) + 10 NAC (2 mM), respectively. 50 μL aliquots were taken from the intestinal sacs at different time intervals (15, 30, 45, 60 minutes) and an equal volume of oxygenated medium was immediately added to the intestinal sacs. The length and width of each intestinal segment were measured after the last sample was taken. The bismuth content transported into the intestinal sacs was measured by ICP-MS as described above.
[0181] In vivo pharmacokinetic studies
[0182] To evaluate the effect of NAC on blood bismuth content, Balb / c mice (n = 3 per group) were orally administered CBS (150 mg / kg), CBS (150 mg / kg) + 3NAC (180 mg / kg), CBS (150 mg / kg) + 10NAC (610 mg / kg), and CBS (150 mg / kg) + 20NAC (1220 mg / kg). The mice were sacrificed 0.5 hours and 1 hour after administration, and about 600 μL of blood from each mouse was collected in a heparinized centrifuge tube. The blood was treated with HNO 3 The bismuth content was measured by ICP-MS. Blood from untreated mice was collected and used as a control to eliminate matrix effects. To measure bismuth accumulation in the mouse lungs, groups of Balb / c mice (3 mice per group) were orally administered CBS (150 mg / kg) + 10 NAC (610 mg / kg) for 1 day, 2 consecutive days, and 3 consecutive days. After perfusing the heart with 0.9% saline, lung tissue was dissected and treated with 69% HNO 3 Acidification for measurement of bismuth content by using ICP-MS.
[0183] In order to measure the detailed pharmacokinetic profile of the optimal NAC and CBS combination determined from the above mouse studies, rats underwent a minor cannulation surgery the day before the experiment, and a polyethylene tube (0.4 mm inner diameter × 0.8 mm outer diameter, Harvard Apparatus, USA) was inserted into the left jugular vein, followed by overnight recovery and fasting. Two groups of rats (5 rats in each group) were orally administered 1 mL aliquots of CBS (150 mg / kg) or CBS (150 mg / kg) + 10 NAC (610 mg / kg). At 0.17, 0.33, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after administration, approximately 200 μL of rat blood was collected from each group via the jugular vein cannula into a heparinized centrifuge tube. Rats were allowed to eat freely 12 hours after administration. All rats were sacrificed 24 hours after administration, and then cardiac perfusion was performed with 200 mL of normal saline to collect major organs, including spleen, liver, lung, kidney and brain, for further analysis. For tissue digestion, a modified protocol from US EPA 3050B (USEPA, 1996) was used. Briefly, approximately 0.2-0.3 g of each rat organ sample was placed in a 15 mL polypropylene tube and digested with 1 mL of 69% HNO 3 Digestion was performed at 65 °C for 16 h, and 100 μL of rat blood was treated with an equal volume of 69% HNO 3Digest at 65°C for 16 hours. After cooling to room temperature, the samples were diluted with 1% nitric acid to a final volume of 3 mL for further use. In order to eliminate matrix effects, blood and organs were also collected from untreated rats and digested under the same conditions for use as blank controls. Standard solutions were prepared by diluting the multi-element calibration standard of bismuth into each organ and blood blank control, respectively. The bismuth content in each organ or blood sample was then measured by ICP-MS and calculated based on the standard curve of each blank control. Non-compartmental analysis including peak concentration (C 最大 ), area under the concentration-time curve (AUC), and C 最大 Time (T 最大 )'s pharmacokinetic parameters.
[0184] Nephrotoxicity test
[0185] The mice groups (4 mice per group) were orally administered with water, CBS (500 mg / kg) and CBS (500 mg / kg) + 3NAC (580 mg / kg) as the vehicle for 4 consecutive days. The mice were killed on days 1, 7, 14, and 28 after the last administration, and the mouse serum was collected for blood urea nitrogen test (ThermoFisher, USA) and creatinine test (CaymanChemical, MI, USA) according to the manufacturer's instructions. The serum isolated from the untreated mice was used as a control.
[0186] Plaque reduction assay
[0187] As described above with slight modifications 40 Plaque reduction assays were performed to determine the 50% antiviral effective dose (EC 50 ). Briefly, one day before the experiment, VeroE6 cells were plated at 4×10 5 Cells were seeded in 12-well tissue culture plates. After 24 h of incubation, 50 plaque-forming units (PFU) of SARS-CoV-2 were added to the cell monolayer in the presence or absence of drug compounds and incubated at 37°C in 5% CO 2The plates were further incubated for 1 h in 4% PBS, and unbound viral particles were then removed by aspirating the medium and washing once with DMEM. The monolayers were then overlaid with Dulbecco's modified eagle's medium (DMEM) containing 1% low melting point agarose (Cambrex Corporation, New Jersey, USA) and the appropriate concentration of a single compound, inverted and incubated as above for another 72 h. The wells were then fixed overnight with 10% formaldehyde (BDH, Merck, Darmstadt, Germany). After removing the agarose plugs, the monolayers were stained with 0.7% crystal violet (BDH, Merck) and the plaques were counted. The percentage of plaque inhibition was determined for each drug compound concentration relative to the control (i.e., no compound added) wells. EC 50 It was calculated using Sigma plot (SPSS) in the Excel plug-in ED50V10. The selectivity index was calculated as CC 50 With EC 50 ratio.
[0188] As previously described with minor modifications (2,15) In studies using NAC, plaque reduction assays were performed to estimate the half maximal effective concentration (EC 50 ). Briefly, one day before the experiment, VeroE6 cells were cultured at 4×10 5 Cells / well were seeded in 12-well tissue culture plates. After 24 h of incubation, 50 plaque-forming units (PFU) of SARS-CoV-2 were added to the cell monolayers in the presence or absence of different concentrations of CBS, NAC, or CBS+3NAC. The cells were incubated at 37°C and 5% CO 2 The plates were further incubated for 1 h under DMEM and unbound viral particles were then removed by aspirating the medium and washing once with DMEM. The monolayers were then covered with medium containing 1% low melting point agarose (Cambrex Corporation, New Jersey, USA) in DMEM and the appropriate concentration of trichostatin A, inverted and incubated as above for another 72 h. The wells were then fixed overnight with 10% formaldehyde (BDH, Merck, Darmstadt, Germany). After removal of the agarose plugs, the monolayers were stained with 0.7% crystal violet (BDH, Merck) and the plaques were counted. The percentage of plaque inhibition was determined for each concentration of drug compound relative to the control (i.e., no compound added) wells. EC 50 It was calculated using Sigma plot (SPSS) in the Excel add-in ED50V10. Plaque reduction assay experiments were performed in triplicate and repeated twice for confirmation.
[0189] Viral load reduction test
[0190] As before with modifications 41 Viral load reduction assays were performed on VeroE6 and Caco2 cells. Supernatant samples from infected cells (0.1 MOI) were harvested 48 h post infection (hpi) for qRT-PCR analysis of viral replication. Briefly, 100 μL of viral supernatant was lysed with 400 μL of AVL buffer, and total RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). As previously described 15 , real-time one-step qRT-PCR was used for quantification of SARS-CoV-2 viral load using QuantiNovaProbe RT-PCR kit (Qiagen) and LightCycler 480Real-Time PCR system (Roche). Each 20 μL reaction mixture contained 10 μL of 2×QuantiNova Probe RT-PCRMaster Mix, 1.2 μL of RNase-free water, 0.2 μL of QuantiNova Probe RT-Mix, 1.6 μL of 10 μM forward primer and reverse primer, 0.4 μL of 10 μM probe, and 5 μL of extracted RNA as template. The reaction was incubated at 45 ° C for 10 minutes for reverse transcription, denatured at 95 ° C for 5 minutes, and then 45 cycles of 5 seconds at 95 ° C and 30 seconds at 55 ° C were performed. Signal detection and measurement were performed in each cycle after the annealing step. Primer and probe sequences were directed against the previously described RNA-dependent RNA polymerase / helicase (RdRP / Hel) gene region of SARS-Cov-2 42 .
[0191] In other studies, SARS-CoV-2-infected (MOI = 0.01) Vero E6 cells were treated with different concentrations of CBS or CBS + 3NAC as previously described with modifications. (13,14), cell culture supernatants were collected at 48 hours post-infection (hpi) for viral RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Primer and probe sequences were for the RNA-dependent RNA polymerase / helicase (RdRP / Hel) gene region of SARS-CoV-2: forward primer: 5'-CGCATACAGTCTTRCAGGCT-3' (SEQ ID NO: 6); reverse primer: 5'-GTGTGATGTTGAWATGACATGGTC-3' (SEQ ID NO: 7); specific probe: 5'-FAMTTAAGATGTGGTGCTTGCATACGTAGAC-IABkFQ-3' (SEQ ID NO: 8). The viral load reduction experiment was performed in triplicate and repeated twice for confirmation.
[0192] Time dosing process test
[0193] Time course experiments were performed to investigate which stage of the SARS-CoV-2 life cycle the compounds interfered with. Briefly, VeroE6 cells were seeded in 24-well plates (2 × 10 5 Cells were infected with SARS-CoV-2 (MOI = 2) and then incubated for 1 hour. The virus inoculum was then removed and the cells were washed twice with PBS. One hour after infection (i.e., after entry), appropriate concentrations of selected drugs were added to the infected cells and then incubated at 37°C, 5% CO 2 Incubate until 9 hours post-infection (i.e., one viral life cycle). For the "-2 to 0 hours post-infection" time point (i.e., pre-incubation), the drug was added 2 hours before SARS-CoV-2 inoculation and removed at 0 hours, followed by viral inoculation as described above. For the "0-1 hour post-infection" time point (i.e., co-infection), the drug was added at 0 hours post-infection together with the viral inoculation, then removed 1 hour post-infection and incubated in fresh medium until 9 hours post-infection. The drug maintained throughout the infection served as a positive control, while DMSO was included in each of the four treatments as a negative control. At 9 hours post-infection, the cell culture supernatant of each time point experiment was collected for measuring viral yield using qRT-PCR as described above.
[0194] For experiments using CBS+3NAC, Vero E6 cells were seeded in 96-well plates (4 × 10 4cells). The cells were infected with SARS-CoV-2HKU-001a at an MOI of 1.5 and then incubated for another hour. The viral inoculum was then removed and the cells were washed twice with PBS. One hour after inoculation (i.e., after entry), CBS+3NAC at a concentration of 1000 μM was added to the infected cells at the indicated time points and then incubated at 37°C, 5% CO 2 The cells were incubated at 4 °C for 10 h post-inoculation (i.e., one complete viral life cycle). The cells were fixed 10 h post-inoculation for quantification of the percentage of infected cells using an immunofluorescence assay targeting SARS-CoV-2 NP.
[0195] Protein purification
[0196] Gene cloning and protein purification were performed as previously described (17,18) The gene encoding the SARS-CoV-2 papain-like protease (PL pro )(ORF1ab polyprotein residues 1564-1882), major protease (M pro The genes encoding SARS-CoV-2 helicase (Hel) (ORF1ab polyprotein residues 3264-3569) were cloned into the expression vector pETH, and the gene encoding SARS-CoV-2 helicase (Hel) (ORF1ab polyprotein residues 16237-18039) was cloned into the expression vector pET28-a(+). The recombinant proteins were overexpressed in Escherichia coli BL21(DE3) and loaded with Ni according to the manufacturer's instructions. 2+ The product was further purified by gel filtration using a HiLoad 16 / 600 Superdex 200 preparative column (GE Life Sciences). The purity of each protein was assessed by 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). Apo-SARS-CoV-2PL pro (20 μM) by Zn 2+ The preparation was dialyzed against chelating buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 2 mM TCEP, 20% glycerol) and excess EDTA was removed by ultrafiltration (Amicon). The concentration of each protein was determined by using a bicinchoninic acid protein assay kit (Sigma-Aldrich).
[0197] Immunofluorescence microscopy
[0198] Vero E6 cells were infected with SARS-CoV-2 (MOI = 0.1) and exposed to water, CBS (1000 μM), NAC (1000 μM), and CBS (1000 μM) + 3NAC (3000 μM) as solvents for 24 hours. The expression of antigens in cells infected with SARS-CoV-2 was detected with an internal rabbit antiserum against the SARS-CoV-2-N nucleocapsid protein (NP). Cell nuclei were labeled with 4,6-diamidino-2-phenylindole (DAPI) nucleic acid stain from Thermo Fisher Scientific (Waltham, MA, USA). Alexa Fluor secondary antibodies were obtained from Thermo Fisher Scientific. Diamond Prolong Antifade mounting medium from Thermo Fisher Scientific was used for mounting.
[0199] Evaluation of selected compounds against SARS-CoV-2 in the Syrian golden hamster model
[0200] Male and female Syrian hamsters aged 6–10 weeks were housed in biosafety-rated housing and given free access to a standard pelleted diet and water as previously described. 19 All experimental protocols were approved by the University of Hong Kong Animal Ethics Committee (CULATR) and performed in accordance with the standard operating procedures of the Biosafety Level 3 Animal Facility (reference code: CULATR 5370-20).
[0201] In the experiment, each hamster was intranasally inoculated with 10 μL of PBS under intraperitoneal ketamine (200 mg / kg) and xylazine (10 mg / kg). 4 PFU of SARS-CoV-2. Six hours after viral challenge, hamsters were intraperitoneally administered Pylorid (150 mg / kg / day) or Remdesivir (25 mg / kg / day) or PBS (untreated control) for four consecutive days.
[0202] Animals were monitored twice daily for clinical signs of disease. Their body weight and survival were monitored for 14 days post infection. Five animals in each group were sacrificed at 4 days post infection for virological and histopathological analysis. Tissue samples of lungs and nasal turbinates were collected. 50 The virus yield in tissue homogenates was detected by qRT-PCR. The cytokine and chemokine profiles of hamster lungs were determined by using a probe-based one-step qRT-PCR (Qiagen) -ΔΔCT The probe and primer sequences for each gene detected are listed in Table 3.
[0203] Table 3. Probe and primer sequences
[0204]
[0205] *SYBR Green-based detection, no probe used
[0206] According to the established scheme 38 , The histopathology of infected animals was examined by H&E staining and immunofluorescence staining.
[0207] To distinguish lung pathology, semiquantitative histological scoring of lung tissue was performed by grading the severity of damage to bronchioles, alveoli, and blood vessels, and the cumulative total score was as follows. Bronchioles: 0, normal structure; 1, mild peribronchiolar infiltration; 2, peribronchiolar infiltration plus epithelial cell death; 3, 2 points and intrabronchiolar wall infiltration and epithelial cell shedding. Alveoli: 0, normal structure; 1, alveolar wall thickening and congestion; 2, focal alveolar cavity infiltration or exudation; 3, diffuse alveolar cavity infiltration or exudation or hemorrhage. Blood vessels: 0, normal structure; 1, mild perivascular edema or infiltration; 2, vascular wall infiltration; 3, severe endothelial infiltration.
[0208] For NAC studies, each hamster was inoculated intranasally with 10 μL of PBS under intraperitoneal ketamine (200 mg / kg body weight) and xylazine (10 mg / kg body weight). 5 pfu of SARS-CoV-2 (SARS-CoV-2HKU-001a). From -3 days post-infection (dpi) to 1 day post-infection, water, CBS, NAC, and CBS+3NAC as solvents were orally administered to hamsters once a day for four consecutive days. Animals were monitored twice a day for clinical signs of disease. Eight animals in each group were euthanized 2 days after infection for virological and histopathological analysis. Lung tissue samples were isolated. The virus yield in tissue homogenates was detected by qRT-PCR. The cytokine and chemokine profiles of hamster lungs were determined by using a probe-based one-step qRT-PCR (Qiagen) 2 -ΔΔCT Method testing. According to established protocols (16) , Histopathology of infected animals was examined by H&E and immunofluorescence staining.
[0209] Gene cloning and construction of SARS-CoV-2 helicase plasmid
[0210] SARS-CoV-2 helicase (i.e., nsp13) is one of the cleavage products (non-structural proteins) of the viral polyprotein ORF1ab. The coding sequence of nsp13 is within the range of 16237 to 18039 of the complete genome of the Wuhan-Hu-1 isolate of severe acute respiratory syndrome coronavirus 2 (NCBI GenBank accession number: NC_045512.2). There is neither a start codon nor a stop codon. In Veriti TM The 96-well thermal cycler (Applied Biosystems) High-fidelity DNA polymerase (New England Biolabs), using nCoV-nsp-13-F (BamHI): CG GGATCCATG GCTGTTGGGGCTTGTGTTCTT (SEQ ID NO: 1) and nCoV-nsp-13-R (XhoI): CCG CTCGAGTCA The DNA fragment of full-length nsp13 was amplified from viral cDNA using the primer pair of TTGTAAAGTTGCCACATTCCTAC (SEQ ID NO: 2). cDNA was synthesized from viral RNA by the Transcriptor First Strand cDNA Synthesis Kit (Roche) using random hexamer primers. Thermal cycling conditions: 98°C for 30 seconds (initial denaturation), followed by 30 amplification cycles (98°C for 30 seconds, 62°C for 10 seconds, and 72°C for 2 minutes). The PCR product was digested by BamHI and XhoI and then inserted into the plasmid pET28-a(+) using T4 DNA ligase to generate pET28-nsp13, which produces His 6 - and T7-tagged helicase. Before sequencing verification, the ligation product was transformed into E. coli DH10B. The verified plasmid pET28-nsp13 was then transformed into E. coli BL21 (DE3).
[0211] Overexpression and purification of SARS-CoV-2 helicase
[0212] E. coli BL21 (DE3) carrying pET28-nsp13 was cultured overnight at 37°C in LB medium supplemented with 50 μg / mL kanamycin. The culture was then expanded in 1 L LB medium at a dilution factor of 1:100 until the OD 600The overexpression of the helicase was induced with 200 mM IPTG at 25 °C for 16 h with stirring at 200 rpm. After overexpression, the bacterial pellet was collected by centrifugation at 5000 g for 10 min at 4 °C and washed once with binding buffer A [20 mM Tris-HCl, pH 6.8, 500 mM NaCl, 20 mM imidazole]. The bacterial pellet was resuspended in 1% Triton X-100 and cOmplete 400 mL of PBS. TM The bacterial lysate was centrifuged at 13000 g for 30 min at 4°C in buffer A with Protease Inhibitor Cocktail (Roche). The supernatant was loaded into 5 mL Ni(II)-charged The recombinant protein was eluted with a linear gradient of elution buffer B [buffer A containing 250 mM imidazole]. The collected eluate fractions were examined by SDS-PAGE, and the purest fractions were pooled and subjected to His 6 -Tag thrombin digestion. The digested protein solution was loaded into 5 mL Chelate on HP column to remove His 6 -Tag and undigested proteins. Use 16 / 600 The product was further purified by gel filtration using a 200 preparative column (GE Life Sciences) and gel filtration buffer C [20 mM Tris-HCl, pH 6.8, 250 mM NaCl]. Protein purification was performed using a FPLC system (GE LifeSciences).
[0213] ATPase assay
[0214] ATPase assay was performed using ATPase assay kit (ab234055, Abcam, Cambridge, MA, USA) based on a modification of the method described previously. 16 The release of phosphate was measured by mixing 2 nM protein with different concentrations of Pylorid in ATPase reaction buffer [20 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 2 mM tris(2-carboxyethyl)phosphine (TCEP)] at 25 °C for 5 min, followed by the addition of 1 μL of 100 mM ATP and 1 μL of 2 mg ml -1Poly(U) was added to each well to initiate the reaction. Approximately 15 μL of the reaction developer was added to each well and allowed to develop for 15 minutes. The absorbance of the mixture was measured at 650 nm using an iD3 multi-mode microplate reader. The relative ATPase activity is the ratio between the activity of the sample in the presence of Pylorid and the activity of the control sample and is therefore expressed as a percentage. The assay was performed in triplicate and repeated on different days.
[0215] FRET-based DNA double-strand unwinding assay
[0216] The FRET-based assay is based on a modified previously described method. 16 DNA oligomers were synthesized and purified by HPLC: FL-Cy3 oligo (5'-TTTTTTTTTTTTTTTTTTTTCGAGCACCGCTGCGGCTGCACC(Cy3)-3') (SEQ ID NO: 3), RL-BHQ oligo (5'-(BHQ2)GGTGCAGCCGCAGCGGTGCTCG-3') (SEQ ID NO: 4) and RL oligo (5'-GGTGCAGCCGCAGCGGTGCTCG-3') (SEQ ID NO: 5) and RL oligo (5'-GGTGCAGCCGCAGCGGTGCTCG-3') (Metabion GmbH, Germany) (18) In annealing buffer [20 mM Tris-HCl pH 8.0, 150 mM NaCl], the two oligomers were mixed at a ratio of 1:1.5 for FL-Cy3:RL-BHQ to a final concentration of 10 μM and 15 μM, respectively, and annealed by heating in a thermal cycler (S1000 TM The FRET assay was performed by heating to 90°C for 2 minutes in a thermal cycler (Bio-Rad) and then slowly cooling to 25°C at a rate of about 1°C / min. ) at 25°C, 10 nM protein was mixed with different concentrations of Pylorid in 48.5 μL of helicase reaction mixture [20 mM Tris-HCl buffer, pH 7.4, 150 mM NaCl, 0.1 mg / mL BSA, 5 mM MgCl 2 , 5mM TCEP, 5% glycerol], then 0.5μL 100mM ATP and 1.5uL oligonucleotide mixture were added to make the final concentrations of FL-Cy3:RL-BHQ oligonucleotide and RL oligonucleotide 5nM and 10nM, respectively. The reaction was incubated for 2 minutes and then used iD3 multi-mode microplate reader measures the change in fluorescence (λ ex=550nm,λ em =620nm) to determine the extent of DNA double-strand unwinding. Relative DNA unwinding activity is the ratio between the activity of the sample in the presence of Pylorid and the activity of the control sample, and is therefore expressed as a percentage. The test was performed in triplicate and repeated on different days.
[0217] For experiments using NAC, SARS-CoV-2 Hel (10 nM) was incubated with various concentrations of CBS and CBS+3NAC in reaction buffer (20 mM Tris-HCl buffer, pH 7.4, 10 mM NaCl, 0.1 mg mL -1 Bovine serum albumin (BSA), 5 mM MgCl 2 , 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), 5% glycerol), and then 0.5 μL 100 mM ATP and 1.5 μL oligonucleotide mixture were added to make the final concentrations of FL-Cy3:RL-BHQ oligonucleotide and RL oligonucleotide 5 nM and 10 nM, respectively. Fluorescence (λ ex =550nm,λ em =620 nm) to determine the unwinding of the DNA double strand. The relative dsDNA unwinding activity is the ratio between the activity of the sample in the presence of the bismuth drug and the activity of the control, and is therefore expressed as a percentage. The experiment was performed in triplicate.
[0218] For the inhibition of ATPase activity in experiments using NAC, the ATPase activity was inhibited by using the method described previously. (18) The release of phosphate was measured by colorimetric detection using an ATPase assay kit (ab234055, Abcam). Generally, SARS-CoV-2 Hel (2 nM) was mixed with different concentrations of CBS and CBS+3NAC in a reaction buffer (20 mM Tris-HCl, pH 6.8, 10 mM NaCl, 5 mM MgCl 2 , 0.5 mM TCEP, 5% glycerol) for 30 min, and then ATP (2 mM) and polyuridylic acid (0.4 mg mL -1 ) to start the reaction. 15 μL of reaction developer was added to the 50 μL reaction system and the color was developed for 15 minutes. The absorbance was measured at 650 nm to determine the ATPase activity. The relative ATPase activity is the ratio between the activity of the sample in the presence of the bismuth drug and the activity of the control, so it is expressed as a percentage. The test was performed in triplicate.
[0219] For PL proActivity inhibition assay, based on previously described methods, using the peptide substrate Arg-Leu-Arg-Gly-Gly↓-AMC (RLRGG↓-AMC, Bachem Bioscience) (SEQ ID NO: 30) for FRET-based assay (19) . SARS-CoV-2PL pro (50 nM) were incubated with different concentrations of CBS and CBS+3NAC in reaction buffer (50 mM HEPES, pH 7.4, 10 mM NaCl, 0.1 mg / ml BSA, 5% glycerol, 0.5 mM TCEP) for 90 min, and then RLRGG↓-AMC (2 μM) was added to start the reaction. After another 30 min of incubation, the fluorescence (λ ex =335nm,λ em =460nm) to determine PL pro Relative PL pro The activity is the ratio between the activity of the sample in the presence of the bismuth drug and the activity of the control and is therefore expressed as a percentage. The assay was performed in triplicate.
[0220] For M pro Activity inhibition assay was based on the previously described method using the peptide substrate Dabcyl-KTSAVLQ↓SGFRKM-E (SEQ ID NO: 29) (Edans)-NH 2 (GL Biochem) for FRET-based detection (17,20) SARS-CoV-2M at room temperature pro The cells were incubated with different concentrations of CBS and CBS+3NAC in a reaction buffer (20 mM Tris-HCl, pH 7.4, 20 1 mM NaCl, 0.1 mg / ml BSA, 5% glycerol, 0.5 mM TCEP) for 30 min, and then Dabcyl-KTSAVLQ↓SGFRKM-E (SEQ ID NO: 29) (20 μM) was added to initiate the reaction. After another 30 min of incubation, the fluorescence (λ ex =335nm,λ em =460nm) to determine M pro Activity. Relative to M pro The activity is the ratio between the activity of the sample in the presence of the bismuth drug and the activity of the control and is therefore expressed as a percentage. The assay was performed in triplicate.
[0221] Bi 3+ Reaction kinetics with proteins
[0222] Bi 3+ With PL proand M pro The reaction kinetics of was investigated by UV-visible spectrophotometry. Briefly, the reaction was first performed in a 96-well microplate ( Protein (PL) was prepared in reaction buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl, 5% glycerol, 0.2 mM TCEP) pro : 20μM and M pro : 30 μM), and then incubated with 30 molar equivalents of CBS at room temperature. The absorbance was recorded at 340 nm and 25 ° C for 20 hours using a SpectraMax iD3 multi-mode microplate reader to monitor the equilibrium state in the kinetic mode. The kinetic data were analyzed by nonlinear square fitting based on a single-phase exponential function using Prism 8.0 (GraphPad Software Inc.) software.
[0223] Michaelis-Menten dynamics
[0224] For the ATPase assay in experiments using pylorid, SARS-CoV-2 helicase (0.5 nM) was incubated with pylorid (0, 0.01, 0.05, 0.1, and 0.5 μM) in a total volume of 50 μL of ATPase reaction mixture at 25 ° C for 30 minutes. To each aliquot of the reaction mixture, 30 μL of reaction developer was added, followed by ATP as substrate to a final concentration of 0.2, 0.5, 1, 2, 4, 6, 8 mM. Control experiments were performed in the absence of inhibitors under the same conditions. V for both the uninhibited and the inhibited reactions was obtained by fitting the data to a double reciprocal Lineweaver-Burk plot. 最大 , K m and Ki values. For the DNA unwinding assay, SARS-CoV-2 helicase (10 nM) was incubated with Pylorid (0, 0.1, 0.2, and 0.5 μM) in the helicase reaction mixture at 25 °C for 5 min. FL-Cy3:RL-BHQ oligonucleotide and RL oligonucleotide were added to the enzyme to give final substrate concentrations of 2.5, 5, 7.5, 10, 15, and 20 nM. Control experiments were performed in the absence of inhibitors under the same conditions. V for both the uninhibited and inhibited reactions were obtained by fitting the data to a double reciprocal Lineweaver-Burk plot. 最大 , K m and the value of Ki.
[0225] For PL pro In the test, the reaction mixture was prepared by adding SARS-CoV-2PL pro(20 nM) was prepared by incubation with CBS + 3NAC (0, 0.1, 0.5, 1 and 2 mM) in a total volume of 100 μL of reaction buffer (50 mM HEPES, pH 7.4, 10 mM NaCl, 0.1 mg / ml BSA, 5% glycerol, 0.5 mM TCEP) at room temperature for 4 hours. In each aliquot of the reaction mixture, the substrate RLRGG↓-AMC was added to obtain a final concentration of 0.5, 1, 2, 5, 10, 20 μM. Control experiments were performed in the absence of inhibitors under the same conditions.
[0226] For M pro In the test, the reaction mixture was prepared by adding SARS-CoV-2PL pro The reaction mixture was prepared by incubating (0.5 μM) with CBS+3NAC (0, 2, 10, 20 μM) in a total volume of 100 μL of reaction buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl, 0.1 mg / ml BSA, 5% glycerol, 0.5 mM TCEP) for 4 hours at room temperature. The substrate Dabcyl-KTSAVLQ↓SGFRKM-E was added to each aliquot of the reaction mixture to obtain a final concentration of 10, 25, 50, 75, 100, 150, 200 μM. Control experiments were performed in the absence of inhibitors under the same conditions. V values for both the uninhibited and the inhibited reactions were obtained by fitting the data to a double reciprocal Lineweaver-Burk plot. 最大 , K m and the value of Ki.
[0227] Zinc supplementation trial
[0228] Apo-SARS-CoV-2 helicase (10 μM) was first prepared by dialysis in zinc (II) chelating buffer [20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 2 mM TCEP]. The apo-protein was then dialyzed overnight at 4°C against excess bismuth (III) nitrate in glycerol dialysis buffer [50 mM Tris-HCl, pH 7.4, 20 mM NaCl, 5 mM TCEP, 20% glycerol], followed by removal of unbound Bi(III) and verification of bound Bi(III) by ICP-MS. The resulting protein was then incubated with ZnSO at a concentration up to 50 molar equivalents relative to SARS-CoV-2. 4 Mix and incubate at room temperature for 2 hours, then perform ATPase assay and DNA unwinding assay as described above.
[0229] UV-Vis Spectroscopy
[0230] UV-visible titrations were performed using 1 cm quartz cuvettes at 25°C at 360 nm / min on a Varian Cary 50 spectrophotometer. 3+ (for Bi(NTA) 3 ) stock solution was titrated stepwise into apo-SARS-CoV-2 helicase (10 μM) in titration buffer [50 mM Tris-HCl, pH 7.4, 20 mM NaCl, 2 mM TCEP]; an equal portion of 2 mM Bi 3+ (for Bi(NTA) 3 ) stock solution was titrated stepwise into the protein (apo-SARS-CoV-2PL) in titration buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl, 1 mM TCEP) pro :10μM,apo-SARS-CoV-2:M pro The titration curves were fitted with the Ryan-Weber nonlinear equation and K was estimated. d .
[0231] Zinc replacement analysis
[0232] SARS-CoV-2 helicase (3 μM) was incubated with 10 μM ZnSO at 4 °C. 4 After incubation in dialysis buffer [20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM TCEP] overnight, unbound Zn(II) ions were removed by dialysis in zinc-free dialysis buffer to ensure that Zn(II) was completely loaded into the protein. The resulting protein was then incubated with different concentrations of Pylorid by dialysis overnight at 4°C with gentle shaking. Subsequently, the sample was dialyzed in dialysis buffer to remove unbound metal ions and then heated at 60°C with concentrated HNO 3 The samples were diluted to a detectable concentration range and 115 In as 209 Bi, 66ICP-MS analysis was performed with an internal standard of Zn (Agilent 7700x, Agilent Technologies, CA, USA). Protein concentration was quantified by a standard bicinchoninic acid (BCA) assay (Thermal Fisher Scientific, USA).
[0233] Zinc release assay.
[0234] Zn after bismuth drug exposure 2+ From SARS-CoV-2PL pro The release of was performed by the previously described method using the zinc-specific fluorophore FluoZinTM-3 (Invitrogen / Life Technologies). (21) In short, SARS-CoV-2PL pro (20 μM) with 0, 2, 5, 20 molar equivalents of Bi 3+ (CBS) was incubated at room temperature for 180 minutes, and then FluoZin-3 (1 μM) was added at room temperature in a total reaction volume of 100 μL (50 mM Tris-HCl, pH 7.4). Fluorescence (λ ex =494nm,λ em =530nm), and using Zn(SO 4 ) 2 The prepared standard curve was converted to Zn 2+ The signal of CBS at the corresponding concentration after mixing with FluoZinTM-3 was recorded for background subtraction. The experiment was performed in triplicate and the results were plotted as [Zn 2+ ] / [PL pro ]Relative 3+ ] / [PL pro ]’s picture.
[0235] Ellman's test
[0236] According to the previously described method (22) The amount of free cysteine was determined spectrophotometrically using DTNB [5,5′-dithiobis(2-nitrobenzoic acid)]. pro (15 μM) with 0, 2, 5, 20 molar equivalents of Bi 3+(CBS) was incubated in 50 μL of reaction buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl) in a 96-well microplate at room temperature for 60 minutes. An equal volume of DTNB (2 mM) was added to the reaction mixture for a total reaction volume of 100 μL. After 90 minutes of incubation, the absorption at 412 nm indicating the release of 5-thiobenzoate anions was detected and converted to thiol concentration using a standard curve prepared with reduced glutathione (GSH) under the same conditions. The experiment was performed in triplicate and the results were plotted as [free cysteine] / [M pro ]Relative 3+ ] / [M pro ]’s picture.
[0237] Statistical analysis
[0238] All statistical analyses were performed using Prism 8.0 (GraphPad Software Inc.) software on three independent experiments and on more experiments if otherwise stated.
[0239] result
[0240] Selected metal compounds exhibit potent activity against SARS-CoV-2 in vitro
[0241] Metal compounds have been used historically as antimicrobial agents; however, their antiviral activity has not been extensively explored. In this study, six metal compounds were selected, including two bismuth citrate-based drugs, colloidal bismuth subcitrate (CBS, De-Nol) and ranitidine bismuth citrate (Pylorid, Jindele), two bismuth (III) porphyrins, Bi(TPP) (TPP: tetraphenylporphyrin salt) and Bi(TPyP) (TPyP: tetrakis(4-pyridyl)porphyrin), an Au(I)-based drug, thiogluconate (Ridaura), and its cell-active form, chloro(triethylphosphine)gold(I) (Au(PEt) 3 )Cl) was used for preliminary screening against SARS-CoV-2 in vitro. The 50% cytotoxic concentration (CC 50 ) were determined to be: 3254±21μM for De-Nol, 2243±43μM for Pylorid, >400μM for both Bi(TPP) and Bi(TPyP), 14.2±1.3μM for Ridaura, and 14.6±1.5μM for Au(PEt 3 )Cl was 13.5±1.8 μM (Table 1).
[0242] Data Table 1 | Cytotoxicity and antiviral activity of selected compounds. CC of selected compounds 50and EC 50 Conclusion
[0243]
[0244] & ND: Not determined.
[0245] # indicates the maximum soluble concentration used in the study.
[0246] * The measurement of drug concentration is based on metal content.
[0247] Next, the four bismuth(III) compounds were prioritized for further evaluation of their CC in human colorectal Caco2 cells due to their promising low cytotoxicity compared to Au(I)-based drugs. 50 The results showed that the CC values ranged from 400 to 3740 μM. 50 To evaluate their antiviral potency, the half maximal effective dose (EC 50 ), De-Nol was 4.6±0.4μM, Pylorid was 2.3±0.5μM, Bi(TPP) was 3.9±1.2μM, and Bi(TPyP) was 7.5±0.9μM. Notably, the addition of all four bismuth(III) compounds at 1 hour post infection (hpi) reduced the viral RNA load in both VeroE6 cells and Caco2 cells in a dose-dependent manner ( Figure 1A -Q). At non-toxic concentrations, De-Nol and Pylorid showed more potent anti-SARS-CoV-2 activity than Bi(TPP) and Bi(TPyP), as evidenced by a maximum of approximately 2-log versus 1-log viral load reduction in VeroE6 cell lysate ( Figures 1A-1D ); a decrease of about 3 log relative to about 2 log in Caco2 cell lysate ( Figure 1E-1H ); VeroE6 cell culture supernatant decreased by about 4 log relative to about 3 log ( Figures 1I-1L ); and a reduction of about 4 log relative to about 3 log in the Caco2 cell culture supernatant ( Figure 1M-1P ) was demonstrated. Bismuth (III) drugs / compounds greatly inhibited SARS-CoV-2, as demonstrated by significantly reduced expression of viral nucleoprotein in drug-treated cells compared to the DMSO-treated group (data not shown, Figure 2A ). In summary, the data demonstrate that bismuth(III) drugs / compounds potently inhibit SARS-CoV-2 replication in vitro.
[0248] To investigate which steps of the SARS-CoV-2 replication cycle are interrupted by the selected drug compounds, a time course experiment was performed by treating virus-infected cells with each compound at different time points and then measuring viral titers at 9 h post-infection, when the first round of progeny viruses was detectable in the cell culture supernatant. Figure 2B and 2C ). Interestingly, the addition of Bi(TPyP) during cell pretreatment or viral co-infection significantly inhibited viral replication, whereas no detectable effect was found when Bi(TPyP) was maintained after viral entry, suggesting that Bi(TPyP) may interfere with SARS-CoV-2 attachment to the cell surface. Pylorid did not affect viral replication when added during the preincubation phase, whereas it reduced viral load by approximately 2 log when added during viral adsorption and post-entry phases, suggesting that Pylorid is a multi-targeted drug that acts during viral entry / internalization or early events after viral entry. To verify this, disruption of viral entry by RBC and Bi(TPyP) was confirmed by pseudotyped virus infection assays, showing that the percentage of viral entry was reduced by approximately 45% and 53% by RBC and Bi(TPyP), respectively ( Figure 2D ). Apparently, both De-Nol and Bi(TPP) act at the post-entry stage. In conclusion, the vulnerability of SARS-CoV-2 after treatment with bismuth(III)-based drugs was demonstrated.
[0249] Therapeutic treatment with Pylorid to alleviate SARS-CoV-2 disease
[0250] Given the exceptionally high selectivity index of Pylorid against SARS-CoV-2 (975) and the unique viral inhibition effect of ranitidine, one of the two components of Pylorid ( Figure 2E ), Pylorid is preferred for in vivo antiviral evaluation. Pylorid is a clinically used drug for the treatment of Helicobacter pylori infection and gastric ulcers, and its safety in human use is well documented. 17 Previous pharmacokinetic studies revealed that Pylorid has a relatively rapid absorption (t 最大 (Bismuth) about 0.5 hours, t 最大 (ranitidine) approximately 2.5 hours) and a small renal clearance (CL r (bismuth) about 40mL / min), the pharmacokinetic behavior is linear within the dose range 18 Recent studies have established an in vivo model to mimic the clinical and pathological manifestations of COVID-19 in golden Syrian hamsters, an excellent tool for studying disease pathogenesis, transmissibility, and antiviral assessment.19 In a preliminary study, intraperitoneal injection of 150 mg / kg / day of Pylorid did not show significant toxicity in animals. Remdesivir was included as a positive control drug, and was administered at 25 mg / kg / day based on its effective dose in SARS-CoV-infected mice. 20 In this study, 10 4 Hamsters were challenged intranasally with PFU SARS-CoV-2 and then given four times a day starting 6 hours after infection. As expected, DMSO-treated control hamsters showed clinical signs of lethargy, hair curling, hunched posture, and shortness of breath from 2 days post-infection (dpi), while hamsters treated with RBC or Remdesivir did not show any clinical signs. Four days after the attack, a study was conducted to examine whether the drug conferred protection against SARS-CoV-2 attack by reducing viral loads in the upper respiratory tract (nasal concha) and lower respiratory tract (lungs). Significantly, Pylorid reduced viral RNA loads in both nasal concha (p<0.05) and lung tissue (p<0.01), by about 1 log and 1.5 log ( Figure 3A ). Consistently, both the remdesivir group and the pylorid group demonstrated inhibition of live SARS-CoV-2 particles in the respiratory tract ( Figure 3B ).
[0251] Increased secretion of pro-inflammatory cytokines and chemokines is associated with severity in afflicted COVID-19 patients 21 To determine whether the therapeutic effect of Pylorid alleviated the virus-induced cytokine storm, the expression levels of interleukin 10 (IL-10) and tumor necrosis factor alpha (TNF-α), which are prognostic markers for severe COVID-19 cases, and representative proinflammatory cytokines and chemokines, including interferon gamma (IFN-γ), CC motif chemokine ligand 22 (CCL22), and CC chemokine receptor type 4 (CCR4), were measured. 22 Interestingly, mRNA expression of IFN-γ (p<0.05), IL-10 (p<0.001), and CCR4 (p<0.05) was significantly reduced in the group of hamsters treated with Pylorid, while these mRNA expressions were generally lower in the Remdesivir group compared with the vehicle (DMSO) group, but not statistically significantly (except for IL-6) (Figure 3c).
[0252] To provide clear monitoring of the disease, histological examination of hematoxylin and eosin (H&E) stained lung tissue was performed 4 days after infection, and significant improvement in lung damage was observed after RBC treatment (data not shown). In the DMSO control group, animals were found to have large areas of consolidation and a large number of alveolar mononuclear infiltration and exudation in the lungs, as well as moderate severity of bronchiolar epithelial cell death. In addition, endothelial cell and vascular wall mononuclear cell infiltration was observed in the pulmonary vessels. The lung tissue of the remdesivir-treated group showed improved morphology but with mild bronchiolar wall infiltration and vascular wall infiltration ( Figure 3E ). However, after RBC treatment, only mild alveolar wall thickening and mild peribronchiolar infiltration were detected, with no visible vascular inflammatory changes (data not shown). Immunofluorescence staining showed that N protein expression in alveolar tissue was reduced after treatment with remdesivir and RBC, mainly expressed in focal bronchiolar epithelial cells in hamster lungs (data not shown, Figure 3F ). In summary, the data therefore demonstrate the effectiveness of RBC by interrupting the replication cycle of SARS-CoV-2 and virus-associated pneumonia in vivo. Pylorid is a potent and irreversible inhibitor of the SARS-CoV-2 helicase.
[0253] Previous studies have shown that bismuth (III) drugs work through a "shotgun" mechanism, targeting multiple biological pathways by binding to key proteins, particularly zinc-containing proteins. 23,24 Given that zinc is often incorporated as zinc fingers or zinc binding domains into several important nonstructural proteins of coronaviruses, such as the PLpro cysteine protease 25 , RNA-dependent RNA polymerase 9 and helicase 26 The hypothesis was that bismuth(III) might functionally inactivate these enzymes, thus prohibiting SARS-CoV-2 viral replication. As a proof of principle, the SARS-CoV-2 helicase was chosen as one of the viable targets to investigate whether bismuth(III) compounds could inactivate the enzyme.
[0254] Helicases are motor proteins that convert NTPs to NDPs and inorganic phosphate (Pi) during ssNA translocation and dsNA separation and unwind both dsRNA and dsDNA with 5′-ss tails along the 5′ to 3′ polarity. 27,28 To explore the potential effect of Pylorid on SARS-CoV-2 helicase, the full-length protein containing the N-terminal zinc binding domain (ZBD) and the C-terminal helicase domain (HEL) was first overexpressed and purified ( Figure 3D ). The study first used a typical phosphate release test 29The ATPase activity of the SARS-CoV-2 helicase was investigated by examining whether bismuth (III) compounds inhibited the ATPase activity of the SARS-CoV-2 helicase, wherein the phosphate released due to ATP hydrolysis was presented as a relative percentage of ATPase activity with or without the addition of bismuth (III) compounds. Figures 4A-4D As shown in Figure 5, with the increase of bismuth (III) concentration, the ATPase activity decreased significantly and the final activity was inhibited by more than 90%. The half maximal inhibitory concentration (IC 50 ) values were calculated to be 1.88 ± 0.12, 0.69 ± 0.12, 2.39 ± 0.02 and 4.68 ± 1.39 μM, respectively (Table 2), indicating the effective inhibition of ATPase activity of SARS-CoV-2 helicase by Pylorid and related bismuth (III) compounds.
[0255] Table 2 | Inhibitory potency of selected compounds against SARS-CoV-2 helicase. IC values of selected compounds against ATPase and DNA unwinding activities of SARS-CoV-2 helicase 50 Summarize
[0256]
[0257] * Drugs are measured based on metal content
[0258] Additional studies followed to investigate the effects of four bismuth compounds on the double-stranded unwinding activity of the SARS-CoV-2 helicase using an established fluorescence resonance energy transfer (FRET)-based assay. 16 . The DNA duplex substrate was prepared by annealing oligomers with a Cy3 fluorophore at the 3' end and a BHQ-2 quencher at the 5' end. Prior to fluorescence titration, the protein and DNA duplex were equilibrated in the presence of different concentrations of bismuth compounds. In the absence of bismuth(III) compounds, the signal intensity of the DNA-duplex increased dramatically due to the unwinding of the Cy3 strand from the DNA-duplex by the helicase. In contrast, in the presence of increasing concentrations of bismuth(III) compounds, the increase in fluorescence was less pronounced, indicating a dose-dependent inhibition of duplex unwinding ( Figure 4E-4H ). Similarly, the IC of the compound against the double-stranded unwinding activity of the enzyme is 50The values were measured as: 1.24 ± 0.02 μM for De-Nol, 0.74 ± 0.13 μM for Pylorid, 3.69 ± 0.26 μM for Bi(TPP), and 2.64 ± 0.16 μM for Bi(TPyP) (Table 2). Notably, such inhibition was irreversible, as supplementation of up to 50 molar equivalents of zinc(II) to the bismuth-bound SARS-CoV-2 helicase resulted in only about 6% of the ATPase activity and about 13% of the double-stranded unwinding activity being restored, indicating that zinc(II) has limited ability to compete with bismuth(III) for SARS-CoV-2 helicase ( Figures 4I-4J From the perspective of enzyme kinetics, increasing the concentration of Pylorid barely changed the maximum velocity (V) of about 42.05 ± 2.78 mM / s. 最大 ) value, and the apparent Michaelis-Menten constant (K m ) increased from 5.51 to 12.74 mM, indicating competitive inhibition of the ATPase activity of SARS-CoV-2 helicase ( Figure 4K-4L ). The inhibition constant (K) of Pylorid against helicase ATPase activity i ) was estimated to be 0.97±0.11 μM. Similarly, Pylorid exhibited a competitive inhibition mode on the double-stranded unwinding activity of the helicase, with a V of approximately 20.53±1.56 nM / min. 最大 The value remains unchanged, K m The value increased from 42.21nM to 91.77nM, K i The value was estimated to be 0.39 ± 0.07 μM. The combined data showed that Pylorid acts as a potent irreversible inhibitor of SARS-CoV-2 helicase.
[0259] Pylorid binds to SARS-CoV-2 helicase and releases zinc ions from the ZBD
[0260] Structural analysis revealed that SARS coronavirus helicase contains three typical zinc fingers, including zinc finger 1 (Cys5, Cys8, Cys26, Cys29), zinc finger 2 (Cys16, Cys19, His33, His39) and zinc finger 3 (Cys50, Cys55, Cys72, His75) 30. Given the high thiophilicity of bismuth(III), subsequent studies therefore investigated by UV-visible spectroscopy whether bismuth(III) competes with zinc(II) in the zinc finger site. In order to exclude interference from ranitidine in Pylorid, a colorless bismuth compound Bi(NTA) was prepared and then titrated into the apo-SARS-CoV-2 helicase. The addition of bismuth(III) to apo-SARS-CoV-2 helicase resulted in the appearance and increase of an absorption band at approximately 340 nm, which is characteristic of the Bi-S ligand to metal charge transfer (LMCT) band. As Figure 5A As shown, the absorption intensity at 340 nm increased and then reached a plateau at a molar ratio of [Bi(III)] / [SARS-CoV-2 helicase] of 3, with a dissociation constant (K) of 1.38 ± 0.05 μM as determined by fitting the data with the Ryan-Weber nonlinear equation. d ). The results showed that each SARS-CoV-2 helicase has three bismuth (III) ions bound, and the cysteine residues at the zinc finger site are involved in the binding.
[0261] Next, the question of whether the binding of bismuth(III) to the SARS-CoV-2 helicase results in the release of zinc(II) was asked by inductively coupled plasma mass spectrometry (ICP-MS). Using equilibrium dialysis, the study showed that approximately 3.46 molar equivalents of zinc(II) were bound to the SARS-CoV-2 helicase. Titration of pylorid with the SARS-CoV-2 helicase resulted in a decrease in the stoichiometry of Zn(II) ions, accompanied by an increase in the stoichiometry of bismuth(III) with the SARS-CoV-2 helicase, ultimately resulting in approximately 2.90 molar equivalents of Zn(II) being replaced, while approximately 2.73 molar equivalents of bismuth(III) were bound to the enzyme ( Figure 5B ). The data confirmed that the inhibition of SARS-CoV-2 helicase by Pylorid was attributed to the replacement of Zn(II) in SARS-CoV-2 helicase by Bi(III) ions.
[0262] discuss
[0263] Metal compounds have been used historically as antimicrobial agents; however, their utility for antiviral therapy has been less explored. This study identified Pylorid, a well-tolerated and effective anti-Helicobacter pylori and anti-ulcer agent. 31, was identified as having potent anti-SARS-CoV-2 activity both in vitro and in vivo. Its efficacy against COVID-19 in an established hamster model is comparable to or even superior to that of remdesivir, which has been approved for emergency use in the United States for COVID-19 treatment, although its long-term side effects remain undetermined. Pylorid's well-characterized safety profile could facilitate its immediate use in clinical trials of COVID-19 patients. The gastrointestinal tract is generally considered to be a target of SARS-CoV-2 32 Pylorid maintains its known good pharmacological activity in the digestive tract environment. Examination of Pylorid on colonic (Caco2) cells showed its potent activity in inhibiting SARS-CoV-2 replication ( Figure 1A-1P ), which could support the use of Pylorid to limit virus-induced gastrointestinal manifestations and potential fecal-oral transmission of COVID-19.
[0264] Growing evidence, including recent findings in a randomized trial, suggests the benefits of combination therapy targeting multiple steps in the SARS-CoV-2 viral life cycle. Triple therapy consisting of betaseron, lopinavir / ritonavir, and ribavirin achieved significantly faster viral clearance and clinical improvement than monotherapy with lopinavir / ritonavir 33 The multisystem manifestations of COVID-19 infection are caused by a combination of virus-induced cellular damage and immune pathology with dysregulated inflammatory activity. The dysregulated cytokine storm combined with a compromised circulatory system results in fulminant multi-organ dysfunction affecting the lungs, heart, kidneys, nerves, muscles, gastrointestinal tract, and brain. 34 This study has demonstrated the possibility of multi-target inhibition of SARS-CoV-2 by Pylorid ( Figure 2C ). The study showed that RBC targets both the entry and post-entry steps of the SARS-CoV-2 replication cycle ( Figure 2C and 2D Helicase was chosen as an illustrative example to demonstrate the in vitro interaction of RBCs with the viral enzyme, namely the irreversible destruction of the enzyme function by releasing active zinc(ii) and potentially forming a non-functional metallodrug-bound enzyme in SARS-CoV-2 infected cells ( Figures 4A-4L Vero E6 cells were used for EC 50These cells do not express TMPRSS2, a major entry determinant for SARS-CoV-244. Clearly, RBCs have achieved higher inhibition efficiency in Calu-3 cells (TMPRSS2+) than in Vero E6 cells (TMPRSS2-), indicating that RBCs interfere with TMPRSS2-triggered viral entry (P<0.01, Figure 2F ). Given that key motifs such as zinc fingers in viral enzymes are highly conserved, Pylorid can be used as a broad-spectrum inhibitor against coronaviruses. 16 Pylorid's high selectivity index and approved safety profile highlight the potential for rapid adoption of the drug for the treatment of COVID-19 disease following further clinical validation.
[0265] Oral administration of bismuth-based drugs in combination with thiol-containing drugs for broad-spectrum anti-coronavirus treatment
[0266] RBC and other related bismuth drugs, such as colloidal bismuth subcitrate (CBS) and bismuth salicylate (BSS), are orally administered antiulcer drugs that precipitate in gastric fluid (pH 1-3) to form a protective coating over the ulcer pits, preventing erosion by gastric secretions. (8) . This could result in reduced systemic absorption and lung concentrations, the primary site of coronavirus (CoV) infection. Additional studies were conducted to stabilize bismuth drugs under acidic conditions so that absorption of bismuth and its efficacy against SAR-CoV-2 could be maintained or enhanced. Studies sought to evaluate whether thiol-containing small molecules could prevent hydrolysis of bismuth drugs under acidic conditions and improve systemic absorption of bismuth drugs and therefore improve efficacy.
[0267] Three thiol-containing drugs (N-acetylcysteine (NAC)), CPL, and PCM) were selected to demonstrate the effect of thiol-containing compounds on the efficacy of bismuth drugs. The initial study verified whether NAC could stabilize the bismuth (III) drug, namely CBS, in simulated gastric fluid (pH 1.2), Dulbecco's phosphate-buffered saline (PBS, pH 7.4), and sodium bicarbonate buffer (pH 9.2). The combination of CBS with different molar equivalents (mol eq.) of NAC is denoted as CBS+nNAC below. Fig. 6AAs shown, CBS precipitated immediately at pH 1.2, and less than 10% of bismuth was found in the supernatant after 1 hour. In contrast, NAC prevented the precipitation of CBS in a dose-dependent manner, with approximately 100% of bismuth remaining in the supernatant in the presence of 3 or 10 molar equivalents of NAC. In addition, NAC similarly prevented the hydrolysis of CBS even at pH 9.2. Moreover, at low pH, NAC stabilized other bismuth drugs, including RBC, bismuth salicylate (BSS), and bismuth subgallate (BSG), and a range of other thiol-containing drugs, including glutathione (GSH), penicillamine (PCM), captopril (CPL), and thiosalicylic acid (TSA) also prevented the hydrolysis of CBS under acidic conditions (data not shown).
[0268] The permeability of bismuth through the simulated gastrointestinal barrier was estimated using a modified parallel artificial membrane permeability assay (PAMPA) in the presence of egg phosphatidylcholine in dodecane (1% wt / vol). After reaching equilibrium in PBS (iso pH 1.2), the cumulative permeation of bismuth by CBS, RBC, and BSS in the presence of 10 molar equivalents of NAC increased from 16.95, 15.24, and 18.80 ng / cm 2 Increased to 24.91, 19.77 and 24.13 ng / cm 2 ( Figure 6B ). This suggests that the chemical stability and permeability of CBS and related bismuth drugs can be potentially modulated by co-administration of thiol-containing drugs.
[0269] Further studies characterized the human intestinal epithelial cancer cell line (Caco-2) (17) and a modified in vitro everted intestinal sac model (at physiological pH 7.4) (18) Bismuth absorption through gastrointestinal segments in the presence or absence of NAC. From Caco-2 permeability assays ( Figure 6C ) showed that in the presence of 10 mol equivalents of NAC, the intestinal permeation of bismuth was moderately increased within 60 min, and the cellular accumulation of bismuth increased from 0.33% to 0.40% ( Fig.6D ). In the presence of 10 molar equivalents of NAC, the permeability (Papp) of human intestinal epithelial cells of CBS increased from 1.66×10 -7 cm / s increased significantly to 2.17×10 -7 cm / s( Fig. 6E In the everted pouch model, the improved intestinal absorption of bismuth by NAC was further demonstrated when CBS was combined with 1, 3, and 10 molar equivalents of NAC, respectively, and the cumulative permeated bismuth increased from 14.68 ng / cm to 14.76 ng / cm within 60 min. 2 Significantly increased to 30.21, 64.98 and 98.61 ng / cm 2 ( Fig. 6F ). In conclusion, the data suggest that oral absorption of bismuth drugs can be potentially improved by co-administration with NAC.
[0270] To investigate the potential of bismuth drugs as oral antiviral agents, the pharmacokinetic properties of CBS in the absence and presence of NAC were evaluated. CBS was administered to Balb / c mice without or with different amounts of NAC, and it was found that when 150 mg / kg CBS was orally co-administered with 3 molar equivalents (180 mg / kg) and 10 molar equivalents (610 mg / kg) of NAC, respectively, blood bismuth concentrations increased significantly from 225.75 to 372.04 and 447.29 μg / L after 0.5 h of exposure, and from 87.27 to 332.76 and 1459.58 μg / L after 1 h of exposure ( Figure 6G The mean blood bismuth concentration of rats after a single oral administration of CBS (150 mg / kg) and its combination with 10 molar equivalents of NAC (610 mg / kg) was plotted against time. Figure 6H As shown, both the CBS group and the CBS+10NAC group showed a double-peak curve. For the CBS group, the blood bismuth level decreased from the first peak of 277.69 μg / L at about 0.5 hours, as previously reported in human studies. (20) It can be seen that the C reaches 447.06μg / L in 4 hours. 最大 The area under the curve (AUC0→12h) value for 0-12 hours was 1316h·μg / L. It is worth noting that the effect of NAC is to increase the peak blood concentration of bismuth to 655.78μg / L and prolong T 最大 (Table 4), resulting in a significant increase in AUC0→12h to 2750h·μg / L.
[0271] Table 4 Pharmacokinetic parameters of CBS and CBS+10NAC after oral administration (n=5).
[0272]
[0273] * The drug doses used in this study were: CBS (150 mg / kg), NAC (610 mg / kg).
[0274] # The measurement of bismuth content is based on the metal content.
[0275] In addition, as revealed by the biodistribution graphs of bismuth in different organs at 24 h, NAC significantly improved bismuth accumulation in the lung (CBS: 552.15 ng / tissue vs. CBS+10NAC: 1056.62 ng / tissue) and kidney (CBS: 6839.76 ng / tissue vs. CBS+10NAC: 18788.60 ng / tissue), moderately promoted bismuth absorption in other organs, namely spleen and liver, and had minimal effect on bismuth absorption in the brain ( Fig.6I ). In summary, both in vitro and in vivo pharmacokinetic data consistently indicate that co-administration of CBS with NAC leads to significantly improved bismuth absorption in both the blood and different organs, which significantly improves the oral availability of bismuth drugs for combating SARS-CoV-2 infection.
[0276] To avoid the potential impact of excessive NAC on antiviral evaluation (22) Bismuth drugs (CBS and BSS) were co-administered with 3 molar equivalents of thiol-containing drugs (NAC, CPL, and PCM) for the following cell-based and animal-based studies. CBS+3NAC treatment reduced SARS-CoV-2 production in Vero E6 cell culture supernatants by up to >3-log10( Fig. 7A ), while NAC alone showed negligible anti-SARS-CoV-2 activity even up to 2000 μM under the same conditions ( Figure 7L ). According to the plaque reduction test, the EC of CBS+3NAC 50 The EC of CBS was estimated to be 5.8 μM. 50 (EC 50 =4.6μM) (1) , indicating that the combined use of CBS and NAC did not impair the antiviral efficacy of CBS. Obviously, against SARS-CoV-2 (B.1.1.7) (4,23) CBS+3NAC treatment significantly reduced virus yields by about 2log10 and about 4log10 in the culture supernatants of Vero E6 cells infected with MERS-CoV and MERS-CoV, respectively, while virus yields in the cell culture supernatants of human embryonic lung fibroblasts (HELF) infected with hCoV-229E were reduced by up to >1.5log10. The results suggest that CBS+3NAC may provide a broad-spectrum antiviral option against epidemic and seasonal coronaviruses.
[0277] The enzyme inhibitory activity of CBS+3NAC against SARS-CoV-2 is shown in Table 5.
[0278] Table 5. Enzyme inhibitory activity of CBS+3NAC against SARS-CoV-2
[0279]
[0280] * The measurement of bismuth content is based on the metal content.
[0281] # ND: Not Determined
[0282] The combination of bismuth drugs (CBS and CBS) with thiol-containing compounds (NAC, CPL, or PCM) inhibited SARS-CoV-2 in Vero E6 cells in a dose-dependent manner. Fig.11 ). The viral load in the cell culture supernatant was quantified by using reverse transcription-qPCR (RT-qPCR).
[0283] Using immunofluorescence staining, the superior antiviral effect of CBS+3NAC was further described by the significantly reduced viral NP antigen in the CBS+3NAC treated group (11.75%) compared to the viral NP antigen in the untreated group (64.5%), CBS treated group (37.25%), or NAC treated group (59.75%) (data not shown, Fig. 7E ). The mode of action of CBS+3NAC was explored by time-dose progression experiments during a single viral replication cycle. Treatment with CBS+3NAC potently blocked SARS-CoV-2 infection, as indicated by a 3.54-log10 and 1.73-log10 decrease in viral load when CBS+3NAC was added during the co-incubation and post-entry phases, respectively; CBS+3NAC was also observed to have little interference with viral attachment (i.e., before incubation, Figure 7F ). Considering that NAC alone had negligible effects on viral replication, this suggests that CBS+3NAC interferes with multiple steps of SARS-CoV-2 internalization and / or post-entry events.
[0284] Given the favorable oral pharmacokinetic properties and expected antiviral efficacy of the CBS and NAC combination in vitro, subsequent studies evaluated its in vivo efficacy in the well-established golden Syrian hamster model. (24) Preliminary studies have shown that when mice were given CBS+3NAC for 3 consecutive days, bismuth levels in the lungs accumulated well ( Figure 7M To achieve optimal antiviral performance, multiple doses of bismuth were administered in the infection model. Equal portions of CBS+3NAC aqueous solution, CBS aqueous solution, NAC aqueous solution, and water (as a vehicle control) were orally administered to hamster groups on days -2, -1, and 6 hours before SARS-CoV-2 intranasal challenge, and on days 0 and 1 after infection ( Figure 7G). The lung viral load of each group was then measured 2 days post infection (dpi), at which time the viral load gradually increased with significant histopathological changes. The number of SARS-CoV-2 RNA copies in the lungs of the CBS+3NAC group was reduced by 15.87 times compared with the vehicle group, which was significantly different (P<0.0001, Kruskal-Wallis and Dunn multiple comparison test) ( Figure 7H ). No statistically significant differences were observed between the vehicle group, CBS group, and NAC group. In addition, the expression of IL-6 gene in the lung was determined to reflect potential respiratory failure and adverse clinical outcomes after viral infection. Fig.7I As shown, CBS+3NAC treatment resulted in a significant 14.4-fold decrease in IL-6 levels compared to the IL-6 levels in the vehicle group, while CBS treatment also resulted in a decrease in IL-6 levels, but the change was not statistically significant. Immunofluorescence staining experiments confirmed the in vivo anti-SARS-CoV-2 efficacy of CBS+3NAC, as demonstrated by a 7.49-fold decrease in the expression of SARS-CoV-2-NP in alveolar tissue of hamster lungs after treatment with CBS+3NAC (data not shown, Figure 7J ).
[0285] Consistently, at the end of the experimental period, infected hamsters in the vehicle group developed signs of lethargy, ruffled hair, hunched posture, and tachypnea, whereas these adverse clinical signs and symptoms were significantly improved in the CBS+3NAC-treated group and slightly alleviated in the CBS-treated group. The severity of lung damage was further examined by histological examination of hamster lung tissues stained with hematoxylin and eosin (H&E). Infected hamsters that received the vehicle developed large areas of consolidation and cellular infiltration in the vascular endothelium as well as the peribronchiolar areas (data not shown). In contrast, these severe pathological changes were greatly prevented in hamsters treated with CBS+3NAC (data not shown), as revealed by the reduction in the estimated lung histology scores from 8.67 to 5.33 and 2.66, respectively ( Figure 7K ), indicating that oral treatment with CBS+3NAC mitigated the risk of progression to severe disease and accelerated recovery. NAC also partially alleviated lung lesions, possibly due to its ability to clear thick mucus in chronic bronchopulmonary disease (15,25) Importantly, due to the antioxidant activity of NAC, it can expand the therapeutic time window of CBS+3NAC during viral or inflammatory phases. (15) .
[0286] In addition, under the same treatment conditions, administration of CBS+3NAC to uninfected Balb / c mice at a converted dose based on body surface area showed only slightly reversible increases in blood urea nitrogen (BUN) and creatinine levels, while no other signs of disease were observed ( Figures 9A-9C ). In conclusion, the study suggests that the bismuth drug, CBS, can be promisingly transformed into an orally usable antiviral agent by co-administration with a thiol-containing drug, NAC, and thus potently reduce the viral RNA and pathogenicity of SARS-CoV-2 in vivo.
[0287] Previous studies have shown that bismuth drugs can feasibly target Zn2+-cysteine complexes of proteins in microorganisms, such as the structural zinc finger domains of SARS-CoV-2 / SARS-CoV helicase (Hel, Nsp13) (1,26) , the catalytic zinc active site of NDM-1 (27) and zinc-binding chaperone protein GroES (28,29) and cysteine proteases such as caspase 3 and caspase 9 (30) The inhibitory effects of CBS+3NAC and CBS on the double-stranded unwinding activity of SARS-CoV-2Hel were comparable, as shown by the IC 50 The IC value of CBS+3NAC is 1.24 μM. 50 The inhibitory effect of CBS+3NAC on ATPase activity was comparable to that of CBS, as shown by the IC 50 The IC value of CBS+3NAC is 1.88 μM. 50 2.3 μM confirmed ( Fig. 8A and 8B Subsequent studies investigated the effects of CBS+3NAC on two unique conserved cysteine proteases encoded by the SARS-CoV-2 genome—papain-like proteases (PLs) that possess conserved structural Zn2+ in the finger subdomains. pro , a domain within Nsp3) and the chymotrypsin-like major protease (Mpro, Nsp5), both of which are required for the proteolytic cleavage of the two large replicase polyproteins (ORF1a and 1ab) for the replication of the viral genome (31) The SARS-CoV-2 PL was evaluated by using a fluorescence resonance energy transfer (FRET)-based cleavage assay with peptide substrates RLRGG↓-AMC and Dabcyl-KTSAVLQ↓SGFRKM-E(Edans)-NH2, respectively. pro and SARS-CoV-2M pro activity. Figure 8C , 8D and Fig. 10A As shown in -B, CBS+3NAC and CBS inhibited SARS-CoV-2 PL in a dose-dependent manner pro ,IC 501.00μM and 1.02μM, respectively, inhibiting SARS-CoV-2M pro ,IC 50 21.10 μM and 22.25 μM, respectively, while NAC showed negligible inhibition at comparable concentrations (Table 6), indicating that the inhibition originated from bismuth ions. Increasing the concentration of CBS+3NAC revealed the maximum velocity (V 最大 ) value remained unchanged at 12.48±0.53nM / s, while the apparent Michaelis-Menten constant (Km) was observed to increase from 176.4 to 320.0nM, indicating that CBS+3NAC had a typical competitive inhibition on SARS-CoV-2Mpro activity with an inhibition constant (Ki) of 6.20±0.40μM; while CBS+3NAC had a typical competitive inhibition on SARS-CoV-2PL pro showed mixed inhibition, possibly due to the binding of Bi3+ to its (multiple) allosteric sites as well as to its active site cysteine ( Fig. 8E and 8F ).
[0288] Table 6. Cytotoxicity and antiviral activity of CBS+3NAC
[0289]
[0290] * The measurement of bismuth content is based on the metal content.
[0291] Detected Bi 3+ SARS-CoV-2PL pro and SARS-CoV-2M pro The incorporation of cysteine residues, such as by adding 20 molar equivalents of Bi 3+ This was demonstrated by the appearance of a characteristic Bi-S ligand to metal charge transfer (LMCT) band at approximately 340 nm when titrated onto various proteins. Figure 8G and 8H ), where t1 / 2(PL pro ) is 62.07 minutes and t1 / 2(M pro ) is 3.38 minutes. 3+ The absorption at 340 nm increased gradually, and then at [Bi3+] / [SARS-CoV-2PL pro ] is about 3 and the molar ratio of [Bi3+] / [SARS-CoV-2M pro ] tended to be stable when the molar ratio was about 1, and the estimated dissociation constants (Kd) were 1.13 μM and 0.60 μM, respectively (Figures 3I, 8I and 3J, 8J). 3+ The combination of 2-Hg and 2-Hg resulted in about 0.78 equivalents of Zn 2+From SARS-CoV-2PL pro This part contributes to the inhibition of its activity. In addition, through the Ellman test, it was found that SARS-CoV-2M pro The amount of free cysteine in the cysteine residues was reduced by about 1 equivalent after binding with Bi3+. This is consistent with previous data ( Figure 7F ), these results suggest that the bismuth drug, CBS+3NAC, may be able to inhibit the expression of cysteinyl proteases by binding to key cysteine proteases, PL pro 、M pro and Hel and functionally inactivate them, blocking multiple biological events during the post-entry phase, ultimately leading to the inhibition of coronavirus replication.
[0292] In conclusion, these studies suggest that combination therapy including the metallodrug CBS and thiol-containing drugs such as NAC could be used as an orally administered broad-spectrum anti-coronavirus regimen by targeting multiple key viral enzymes.
[0293] References
[0294] 1 Zhou, et al. Nature 579, 270-273, doi:10.1038 / s41586-020-2012-7(2020).
[0295] 2 Stadler, et al. SARS-Nat Rev Microbiol 1, 209-218 (2003).
[0296] 3 Wrapp,.et al.Science 367,1260-1263,doi:10.1126 / science.abb2507(2020).
[0297] 4 Lan, et al. Nature, doi:10.1038 / s41586-020-2180-5(2020).
[0298] 5 Shang, et al. SNature, doi:10.1038 / s41586-020-2179-y (2020).
[0299] 6 Sheahan, et al. Sci Transl Med, doi:10.1126 / scitranslmed.abb5883 (2020).
[0300] 7 Zhang, et al.Science,doi:10.1126 / science.abb3405(2020).
[0301] 8 Jin,et al.Nature,doi:10.1038 / s41586-020-2223-y(2020).
[0302] 9 Gao,et al.Science,doi:10.1126 / science.abb7498(2020).
[0303] 10 Sanders, et al JAMA, doi:10.1001 / jama.2020.6019(2020).
[0304] 11 Serafin,et al.Int J Antimicrob Agents,105969,doi:10.1016 / j.ijantimicag.2020.105969(2020).
[0305] 12 Munster, et al. bioRxiv,2020.2003.2021.001628,doi:10.1101 / 2020.03.21.001628(2020).
[0306] 13 https: / / www.nih.gov / news-events / news-releases / nih-clinical-trial-shows-remde sivir-accelerates-recovery-advanced-covid-19
[0307] 14 Wang,et al.Lancet 395,1569-1578,doi:10.1016 / S0140-6736(20)31022-9(2020).
[0308] 15 Chan,et al.Lancet 395,514-523,doi:10.1016 / S0140-6736(20)30154-9(2020).
[0309] 16 Yang,et al.Angew.Chem.Int.Ed.Engl.46,6464-6468,doi:10.1002 / anie.200701021(2007).
[0310] 17 Pipkin,et al.Pharmacoepidemiol.Drug Saf.5,399-407,doi:10.1002 / (sici)1099-1557(199611)5:6<399::Aid-pds243>3.0.Co;2-4(1996).
[0311] 18 KOCH,et al.Br.J.Clin.Pharmacol.42,201-205,doi:10.1046 / j.1365-2125.1996.03929.x(1996).
[0312] 19 Chan,et al.Clin.Infect.Dis.,doi:10.1093 / cid / ciaa325(2020).
[0313] 20 Wang,et al.Cell Res 30,269-271,doi:10.1038 / s41422-020-0282-0(2020).21 Tay,et al Nat.Rev.Immunol.,doi:10.1038 / s41577-020-0311-8(2020).
[0314] 22 Huang,et al.Lancet 395,497-506,doi:10.1016 / S0140-6736(20)30183-5(2020).
[0315] 23 Wang,et al.Nat Commun 9,439,doi:10.1038 / s41467-018-02828-6(2018).
[0316] 24 Cun,et al P Natl Acad Sci USA 107,4943-4948,doi:10.1073 / pnas.0913970107(2010).
[0317] 25 Baez-Santos,et al Antivir Res 115,21-38,doi:10.1016 / j.antiviral.2014.12.015(2015).
[0318] 26 Jia,et al.Nucleic Acids Res 47,6538-6550,doi:10.1093 / nar / gkz409(2019).27 Patel,et al.J.Biol.Chem.281,18265-18268,doi:10.1074 / jbc.R600008200(2006).
[0319] 28 Keum,et al Biochem Pharmacol 84,1351-1358,doi:10.1016 / j.bcp.2012.08.012(2012).
[0320] 29 Tanner,et al.J.Biol.Chem.278,39578-39582,doi:10.1074 / jbc.C300328200(2003).
[0321] 30 Jia,et al.Nucleic Acids Res.47,6538-6550,doi:10.1093 / nar / gkz409(2019).
[0322] 31 Bardhan,et al Gut 41,181-186,doi:10.1136 / gut.41.2.181(1997).
[0323] 32 Lin,L.et al.Gastrointestinal symptoms of 95 cases with SARS-CoV-2infection.Gut 69,997-1001,doi:10.1136 / gutjnl-2020-321013(2020).
[0324] 33 Hung,et al.Lancet,doi:10.1016 / S0140-6736(20)31042-4(2020).
[0325] 34 Roberts,M.et al.Covid-19:a complex multisystem clinicalsyndrome.at https: / / blogs.bmj.com / bmj / 2020 / 05 / 01 / covid-19-a-complex-multisystem-clinical-syndrome / (2020).
[0326] 35 Li,et al Curr.Opin.Chem.Biol.16,74-83,(2012).
[0327] 36 Wang,et al.B iScience 23,101054,doi:https: / / doi.org / 10.1016 / j.isci.2020.101054(2020).
[0328] 37 Chu, et al. Lancet Microbe 1,e14-e23,doi:https: / / doi.org / 10.1016 / S2666-5247(20)30004-5(2020).
[0329] 38 Yuan,et al..Nat.Commun.10,120,doi:10.1038 / s41467-018-08015-x(2019).
[0330] 39 Yuan,et al.J.Antimicrob.Chemother.71,2489-2497,doi:10.1093 / jac / dkw194(2016).
[0331] 40 Chan,et al.T Antiviral Res.160,38-47,doi:https: / / doi.org / 10.1016 / j.antiviral.2018.10.007(2018).
[0332] 41 Yuan,et al.Antimicrob.Agents Chemother.59,4082-4093,doi:10.1128 / aac.00306-15(2015).
[0333] 42 Chan,et al.J.Clin.Microb.58,e00310-00320,doi:10.1128 / jcm.00310-20(2020).
[0334] 1.Yuan,et al.Nat.Microb.5,1439–1448((2020).
[0335] 2.World Health Organization.Coronavirus Disease(COVID-19)SituationReports.https: / / www.who.int / emergencies / diseases / novel-coronavirus-2019 / situation-reports.,(2020).
[0336] 3.Graham,Science 368,945-946(2020).
[0337] 4.Emerging SARS-CoV-2 variants.Centers for Disease Control andPrevention.https: / / www.cdc.gov / coronavirus / 2019-ncov / more / science-and-research / scientific-brief-emerging-variants.html#_ftn1.(2021).
[0338] 5.Zumla,et al.Nat.Rev.Drug Discov.15,327-347(2016).
[0339] 6.Beigel,et al.N.Engl.J.Med.383,994(2020).
[0340] 7.Goldman,et al.N.Engl.J.Med.383,1827-1837(2020).
[0341] 8.Sun,Curr.Opin.Chem.Biol.16,74-83(2012).
[0342] 9.D.C.Wolf,C.H.Wolf,D.T.Rubin,Temporal improvement of a COVID-19-positive Crohn's disease patient treated with bismuth subsalicylate.Am.J.Gastroenterol.115,1298(2020).
[0343] 10.Wang,et al.Acc.Chem.Res.52,216-227(2019).
[0344] 11.Sadler,et al.Chem.Eur.J.2,701-708(1996).
[0345] 12.Prescott,et al.Br.Med.J.2,1097-1100(1979).
[0346] 13. Prescott, et al. Lancet 2,432-434 (1977).
[0347] 14.Smilkstein,et al.N.Engl.J.Med.319,1557-1562(1988).
[0348] 15.Omara,et al.Toxicology 116,219-226(1997).
[0349] 16.Shi,et al.Ther.Clin.Risk Manag.16,1047-1055(2020).
[0350] 17.Ye,et al.J.Med.Chem.63,7695-7720(2020).
[0351] 18.Alam,et al.J.Pharm.Pharmacol.64,326-336(2011).
[0352] 19.Leussink,et al.Arch.Toxicol.74,349-355(2000).
[0353] 20.Hespe,et al..Lancet 332,1258(1988).
[0354] 21.Riva,et al.Nature 586,113-119(2020).
[0355] 22.Geiler,et al..Biochem.Pharmacol.79,413-420(2010).
[0356] 23.Kemp,et al...bioRxiv,2020.2012.2014.422555(2020).
[0357] 24.Chan,et al..Clin.Infect.Dis.71,2428-2446(2020).
[0358] 25.Dekhuijzen,Eur.Respir.J.23,629-636(2004).
[0359] 26.Yang,et al..Angew.Chem.Int.Ed.46,6464-6468(2007).
[0360] 27.Wang,et al.Nat.Commun.9,439(2018).
[0361] 28.S.Cun,H.Sun,Azinc-binding site by negative selection inducesmetallodrugsusceptibility in an essential chaperonin.Proc.Natl.Acad.Sci.U.S.A.107,4943(2010).
[0362] 29.Cun,et al..J.Biol.Chem.283,15142-15151(2008).
[0363] 30.Wang,et al.iScience 23,101054(2020).
[0364] 31.Lei,et al.Antivir.Res.149,58-74(2018).
Claims
1. Use of a composition comprising an effective amount of one or more bismuth (III) compounds or pharmaceutically acceptable salts thereof and one or more thiol-containing small molecule compounds in a pharmaceutically acceptable carrier in the preparation of a medicament for treating SARS-CoV-2 infection in a subject, wherein the composition reduces one or more symptoms of SARS-CoV-2 infection; wherein, The bismuth (III)-containing compound is colloidal bismuth subcitrate, and the thiol-containing small molecule compound is N-acetylcysteine.
2. The method of claim 1, wherein the effective amount of one or more bismuth (III)-containing compounds effectively inhibits the helicase protein of SARS-CoV-2 in the subject.
3. The use of claim 1, wherein the bismuth (III) compound or a pharmaceutically acceptable salt thereof is administered systemically.
4. The use according to claim 1, wherein the bismuth (III) compound or a pharmaceutically acceptable salt thereof is administered orally or parenterally.
5. The use of claim 1, wherein probenecid or a pharmaceutically acceptable salt thereof is administered in an amount effective to reduce viral replication.
6. The method of claim 1, wherein the bismuth (III) compound or a pharmaceutically acceptable salt thereof is administered in an effective amount to reduce one or more symptoms of a disease, disorder or condition associated with the coronavirus.
7. The use of claim 6, wherein the symptoms include fever, sinus and / or lung congestion, runny or stuffy nose, cough, sneezing, sore throat, body aches, fatigue, shortness of breath, chest tightness, wheezing when breathing out, chills, muscle aches, headache, diarrhea, tiredness, nausea, vomiting, and combinations thereof.
8. The use of claim 1, wherein the subject currently has a SARS-CoV-2 infection.
9. The use of claim 8, wherein the subject suffers from COVID-19.
10. The use of claim 1, wherein the subject has been exposed to the SARS-CoV-2 but is asymptomatic.
11. The use according to any one of claims 1 to 10, wherein the composition is in the form of a tablet for oral administration.
12. The use according to any one of claims 1 to 10, wherein the composition is in a form suitable for injection.
13. A dosage form comprising an effective amount of colloidal bismuth subcitrate: which inhibits SARS-CoV-2 helicase protein in a subject after administration in combination with 3 or 10 molar equivalents of a thiol-containing small molecule compound; in, The dosage form further comprises one or more thiol-containing small molecule compounds, wherein the thiol-containing small molecule compound is N-acetyl cysteine.
14. The dosage form of claim 13, wherein the dosage form is a tablet or a capsule.
15. The dosage form of claim 13, wherein the dosage form is an injection.
16. The use according to claim 1, wherein The thiol-containing small molecule compound is in an effective amount to stabilize the bismuth (III) compound or a pharmaceutically acceptable salt thereof at low pH.
17. The use according to claim 1, wherein The thiol-containing small molecule compound is in an effective amount to stabilize the bismuth (III) compound or a pharmaceutically acceptable salt thereof at pH 1.2.
